Skip to main content
×
×
Home
  • Print publication year: 2014
  • Online publication date: June 2014

Section 7 - Disease-specific neurorehabilitation systems

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Textbook of Neural Repair and Rehabilitation
  • Online ISBN: 9780511995590
  • Book DOI: https://doi.org/10.1017/CBO9780511995590
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×

References

1. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002; 8: 448–60.
2. Stern Y. Cognitive reserve. Neuropsychologia 2009; 47: 2015–28.
3. Katzman R, Aromsom M, Fuld P, et al. Development of dementing illnesses in an 80 year old volunteer cohort. Ann Neurol 1989; 25: 317–24.
4. Satz P. Brain reserve capacity and symptom onset after brain injury: a formulation and review of evidence for threshold theory. Neuropsychology 1993; 7: 273–95.
5. Stern Y. Cognitive reserve and Alzheimer's disease. Alzheimer Dis Assoc Disord 2006; 20: S69–74.
6. Fratiglioni L, Wang H-X. Brain reserve hypothesis in dementia. J Alzheimers Dis 2007; 12: 1–22.
7. Fotenos AF, Mintum MA, Snyder AZ, et al. Brain volume decline in aging. Arch Neurol 2008; 65: 113–20.
8. Ikran MA, Vrooman HA, Vernooij MW, et al. Brain tissue volumes in relation to cognitive function and risk of dementia. Neurobiol Aging 2010; 31: 378–86.
9. Valenzuela MJ. Brain reserve and the prevention of dementia. Curr Opin Psychiatry 2008; 21: 296–302.
10. The Canadian Study of Health and Aging. Risk factors for Alzheimer's disease in Canada. Neurology 1994; 44: 2073–80.
11. Zhang M, Levy P, Klauber MR, et al. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990; 27: 428–37.
12. Snowden DA, Kemper SJ, Mortimer JA, et al. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the nun study. JAMA 1996; 275: 528–32.
13. Alexander GE, Furey M, Grady CL, et al. Association of premorbid function with cerebral metabolism in Alzheimer's disease: implication for the reserve hypothesis. Am J Psychiatry 1997; 154: 165–72.
14. Stern Y, Alexander GE, Prohovnik I, et al. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol 1992; 32: 371–5.
15. Stern Y, Tang M-X, Denaro J, et al. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann Neurol 1995; 37: 590–5.
16. Hall CB, Derby C, LeVally A, et al. Education delays accelerated decline on a memory test in persons who develop dementia. Neurology 2007; 69: 1657–64.
17. Scarmeas N, Albert SM, Manly JL, et al. Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77: 308–16.
18. Bennett DA, Wilson RS, Scheider JA, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003; 60: 1909–15.
19. Buschert V, Bokde ALW, Hampel H. Cognitive intervention in Alzheimer disease. Nat Rev Neurol 2010; 6: 508–17.
20. Backman L, Almkvist O, Andersson JLR, et al. Brain activation in younger and older adults during implicit and explicit retrieval. J Cogn Neurosci 1997; 9: 378–91.
21. Backman L, Almkvist O, Nyberg L, et al Functional changes in brain activity during priming in Alzheimer's disease. J Cogn Neurosci 2000; 12: 134–41.
22. Sperling RA, Bates JF, Chua EF, et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 44–50.
23. Grossman M., Koenig P, Glosser G, et al. Neural basis for semantic memory difficulty in Alzheimer's disease: an fMRI study. Brain 2003; 126: 292–311.
24. Grossman M, Koenig P, DeVita C, et al. Neural basis for verb processing in Alzheimer's disease: an fMRI study. Neuropsychology 2004; 17: 658–74.
25. Perrault A, Wolfson C, Egan M, et al. Prognostic factors for functional independence in older adults with mild dementia: results from the Canadian study of health and aging. Alzheimer Dis Assoc Disord 2002; 16: 239–47.
26. Aguero-Torres H, Qiu C, Wimblad B, et al. Dementing disorders in the elderly: evolution of the disease severity over 7 years. Alzheimer Dis Assoc Disord 2002; 16: 221–7.
27. Qiu C, Kivipelto M, von Strauss E. State of the Art. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 9: 111–28.
28. Glisky EL. Acquisition and transfer of word processing skills by an amnesic patient. Neuropsychol Rehabil 1995; 5: 299–318.
29. Glisky EL, Schacter DL. Acquisition of domain specific knowledge in patients with organic memory disorders. J Learn Disabil 1988; 21: 333–51.
30. Verghese J, Lipton RB, Katz, MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003; 348: 2508–16.
31. Bennett H, Corbett AJ, Gaden S, et al. Subcortical vascular disease and functional decline: a 6-year predictor study. J Am Geriatr Soc 2002; 50: 1969–77.
32. Boyle PA, Paul R, Moser D, et al. Cognitive and neurologic predictors of functional impairment in vascular dementia. Am J Geriatr Psychiatry 2003; 11: 103–6.
33. Glosser G, Gallo J, Duda N, et al. Visual perceptual functions predict instrumental activities of daily living in patients with dementia. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15: 198–206.
34. Schwartz MF, Reed ES, Montgomery M, et al. The quantitative description of action disorganization after brain damage: a case study. Cogn Neuropsychol 1991; 8: 381–414.
35. Schwartz MF, Montgomery M, Fitzpatrick-DeSalme EJ, et al. Analysis of a disorder of everyday action. Cogn Neuropsychol 1995; 12: 86–92.
36. Shallice T. From Neuropsychology to Mental Structure. Cambridge: Cambridge University Press, 1988.
37. Giovannetti T, Libon DJ, Hart T. Awareness of naturalistic errors in dementia. J Int Neuropsychol Soc 2002; 8: 633–44.
38. Feyereisen P, Gendron M, Seron X. Disorders of everyday actions in subjects suffering from senile dementia of Alzheimer's type: an analysis of dressing performance. Neuropsychol Rehabil 1999; 9: 169–88.
39. Gitlin LN, Earland TV. Dementia (improving quality of life in individuals with dementia: the role of nonpharmacologic approaches in rehabilitation). In Stone JH, Blouin M, eds. International Encyclopedia of Rehabilitation. New York, NY: Springer, 2011.
40. Clare L, Wilson BA, Carter G, et al. Assessing awareness in early-stage Alzheimer's disease: development and piloting of the Memory Awareness Rating Scale. Neuropsychol Rehabil 2002; 12: 341–62.
41. Hardy RM, Oyebode JR, Clare L. Measuring awareness in people with mild to moderate Alzheimer's disease: development of the Memory Awareness Rating Scale-Adjusted. Neuropsychol Rehabil 2006; 16: 178–93.
42. Ownsworth T, Clare L, Morris R. An integrated biopsychosocial approach to understanding awareness deficits in Alzheimer's disease and brain injury. Neuropsychol Rehabil 2006; 16: 415–38.
43. Wilson BA. Editorial: how do we know that rehabilitation works? Neuropsychol Rehabil 1993; 3: 1–4.
44. Wilson BA. Towards a comprehensive model of cognitive rehabilitation. Neuropsychol Rehabil 2002; 12: 97–110.
45. Clare L, Woods RT, Moniz Cook ET, et al. Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev 2003; 4: CD003260.
46. Sitzer DI, Twamley EW, Jeste DV. Cognitive training in Alzheimer's disease. Acta Psychiatry Scand 2006; 114: 75–90.
47. Alderman N. Central executive deficit and response to operant conditioning methods. Neuropsychol Rehabil 1996; 6: 161–86.
48. Son GR, Therrien B, Whall A. Implicit memory and familiarity among elders with dementia. J Nurs Scholarship 2002; 34: 263–7.
49. Wilson BA, Baddeley A, Evans J, et al. Errorless learning in the rehabilitation of memory impaired people. Neuropsychol Rehabil 1994; 4: 307–26.
50. Baddeley AD. Implicit memory and errorless learning: a link between cognitive theory and neuropsychological rehabilitation? In Squire LR, Butters N, eds. Neuropsychology of Memory. 2nd edn. New York, NY: The Guildford Press, 1992; 309–14.
51. Evans JJ, Wilson BA, Schuri U, et al. A comparison of “errorless” and “trial-and-error” learning methods for teaching individuals with acquired memory deficits. Neuropsychol Rehabil 2000; 10: 67–101.
52. Hunkin NM, Squires EJ, Aldrich FK, et al. Errorless learning and the acquisition of word processing skills. Neuropsychol Rehabil 1998; 8: 433–49.
53. Glisky EL, Schacter DL, Tulving E. Learning and retention of computer related vocabulary in memory impaired patients: methods of vanishing cues. J Clin Exp Psychol 1986; 8: 292–312.
54. Bier N, Provencher V, Gagnon L, et al. New learning in dementia: transfer and spontaneous use of learning in everyday life functioning. Two case studies. Neuropsychol Rehabil 2008; 18: 204–35.
55. Gilmore GC, Cronin-Golomb A, Neargarder SA, et al. Enhanced stimulus contrast normalizes visual processing of rapidly presented letters in Alzheimer's disease. Vision Res 2005; 45: 1013–20.
56. Oswald WD, Rupprecht R, Gunzelmann T, et al. The SIMA-project: effects of 1 year cognitive and psychomotor training on cognitive abilities of the elderly. Behav Brain Res 1996; 78: 67–72.
57. Ball K, Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults. JAMA 2002; 288: 2271–81.
58. Neely AS, Backman L. Maintenance of gains following multifactorial and unifactorial memory training in late adulthood. Educ Gerontol 1993; 19: 105–17.
59. Josephsson S. Supporting everyday activities in dementia. Int Psychogeriatr 1996; 8: 141–4.
60. Tate RL. Beyond one-bun, two-shoe: recent advances in the psychological rehabilitation of memory disorders after acquired brain injury. Brain Inj 1997; 11: 907–18.
61. Woods B. Management of memory impairment in older people with dementia. Int Rev Psychiatry 1994; 6: 153–61.
62. Backman L. Memory training and memory improvement in Alzheimer's disease: rules and exceptions. Acta Neurol Scand 1992; 139: 84–9.
63. Schacter DL, Rich SA, Stampp MS. Remediation of memory disorders: experimental evaluation of the spaced-retrieval technique. J Clin Exp Neuropsychol 1985; 7: 79–96.
64. Camp CJ, Stevens AB. Spaced retrieval: a memory intervention for dementia of the Alzheimer's type (DAT). Clin Gerontol 1990; 10: 651–8.
65. Lekeu F, Wojtasik V, Van der Linden M, et al. Training early Alzheimer's patients to use a mobile phone. Acta Neurol Belg 2002; 102: 114–21.
66. Kinsella GJ, Ong B, Storey E, et al. Elaborated spaced-retrieval and prospective memory in mild Alzheimer's disease. Neuropsychol Rehabil 2007; 1: 688–706.
67. Hopper T Drefs SJ, Bayles KA, et al. The effects of modified spaced-retrieval training on learning and retention of face–name associations by individuals with dementia. Neuropsychol Rehabil 2010; 20: 81–102.
68. Zanetti O, Zanieri G, DiGiovanni G, et al. Effectiveness of procedural memory stimulation in mild Alzheimer's disease: a controlled study. Neuropsychol Rehabil 2001; 11: 263–72.
69. Tappan RM. The effect of skill training on functional abilities of nursing home residents with dementia. Res Nurs Health 1994; 17: 159–65.
70. Rossler A, Seifritz E, Krauchi K, et al. Skill learning in patients with moderate Alzheimer's disease: a prospective pilot study of waltz lessons. Int J Geriatr Psychiatry 2002; 17: 1155–6.
71. Cott CA, Dawson P, Sidani S, et al. The effects of a walking/talking program on communication, ambulation, and functional status in residents with Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16: 81–7.
72. Etnier JL, Salazar W, Landers DM, et al. The influence of physical fitness and exercise upon cognitive functioning: a meta-analysis. J Sport Exer Psychol 1997; 19: 249–77.
73. Bozeat S, Patterson K, Hodges J. Relearning object use in semantic dementia. Neuropsychol Rehabil 2004; 14: 351–63.
74. Jokel R, Rochon E, Leonard C. Treating anomia in semantic dementia: improvement, maintenance, or both? Neuropsychol Rehabil 2006; 16: 241–56.
75. Jokel R, Ronchon E, Anderson ND. Errorless learning of computer-generated words in a patient with semantic memory. Neuropsychol Rehabil 2010; 20: 16–41.
76. Hutton S, Sheppard L, Rusted JM, et al. Structuring the acquisition and retrieval environment to facilitate learning in individuals with dementia of the Alzheimer type. Memory 1996; 4: 113–30.
77. Dick MB, Shankle RW, Beth RE, et al. Acquisition and long term retention of a gross motor skill in Alzheimer's disease patients under constant and varied practice conditions. J Gerontol 1996; 51: 103–11.
78. Dick MB, Andel R, Hseih S, et al. Contextual interference and motor skill learning in Alzheimer's disease. Aging Neuropsychol Cogn 2000; 7: 273–87.
79. Dick MB, Hsieh S, Bricker J, et al. Facilitation acquisition and transfer of a continuous motor task in healthy older adults and patients with Alzheimer's disease. Neuropsychology 2003; 17: 202–12.
80. Dick MB, Andel R, Bricker J, et al. Dependence on visual feedback during motor skill learning in Alzheimer's disease. Aging Neuropsychol Cogn 2001; 8: 120–36.
81. Clare L, Wilson BA, Breen K, et al. Errorless learning of face–name associations in early Alzheimer's disease. Neurocase 1999; 5: 37–46.
82. Clare L, Wilson BA, Carter G, et al. Intervening with everyday memory problems in dementia of Alzheimer's type: an errorless learning approach. J Clin Exp Neuropsychol 2000; 22: 132–46.
83. Clare L, Wilson BA, Carter G, et al. Relearning face–name associations in early Alzheimer's disease. Neuropsychology 2002; 16: 538–47.
84. Clare L, Wilson BA, Carter G, et al. Long-term maintenance of treatment gains following a cognitive rehabilitation intervention in early dementia of Alzheimer type: a single case study. Neuropsychol Rehabil 2001; 11: 477–94.
85. Clare L, Wilson BA, Carter G, et al. Depression and anxiety in memory clinic attenders and their carers: implication for evaluating the effectiveness of cognitive rehabilitation interventions. Int J Geriatr Psychiatry 2002; 17: 962–7.
86. Dunn J, Clare L. Learning face–name associations in early-stage dementia: comparing the effects of errorless learning and effortful processing. Neuropsychol Rehabil 2007; 17: 735–54.
87. Haslam C, Gilroy D, Black S, et al. How successful is errorless learning in supporting memory for high- and low-level knowledge in dementia? Neuropsychol Rehabil 2006; 16: 505–36.
88. Bier N, Van Der Linden M, Gagnon L, et al. Face–name association in early Alzheimer's disease: a comparison of learning methods and their underlying mechanisms. Neurospychol Rehabil 2008; 18: 343–71.
89. Olzaran J, Muniz R, Reisberg B, et al. Benefits of cognitive motor intervention in MCI and mild to moderate Alzheimer's disease. Neurology 2004; 63: 2348–53.
90. Bottino CMC, Carvalho IAM, Alvarez AMMA, et al. Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patient: a pilot study. Clin Rehabil 2005; 19: 861–9.
91. Hebert R, Dubois MF, Wolfson C, et al. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian study of health and aging. J Gerontol A Med Sci 2001; 56: M693–9.
92. Knopman DS, Berg JD, Thomas R, et al. Nursing home placement is related to dementia progression–experience from a clinical trial. Neurology 1999; 52: 714–8.
93. Volicer L, Hurley AC. Management of behavioral symptoms in progressive degenerative dementias. J Gerontol A Med Sci 2003; 58: M837–45.
94. Boucher LA. Disruptive behaviors in individuals with Alzheimer's disease: a behavioral approach. Am J Alzheimers Dis 1999; 14: 351–6.
95. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001; 9: 361–81.
96. Gitlin LN, Winter L, Dennis M, et al. A non-pharmacological intervention to manage behavioral and psychological symptoms of dementia and reduce caregiver distress: design and methods of project ACT. Clin Interv Aging 2007; 2: 695–703.
97. Mittelman MS. Nonpharmacologic management and treatment: effect of support and counseling on caregivers of patients with Alzheimer's disease. Int Psychogeriatry 2000; 12: 341–6.
98. Moniz-Cook E, Veroonij-Dassen M. Timely psychosocial intervention in dementia: a primary care perspective. Dementia 2006; 5: 307–15.
99. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7: 1–63.
100. Hasselkus BR, Murray BJ. Everyday occupation, well-being, and identity: the experience of caregivers in families with dementia. Am J Occup Ther 2007; 61: 9–20.
101. Lee CC, Czaja SJ, Schultz R. The moderating influence of demographic characteristics, social support, and religious coping on the effectiveness of a multicomponent psychosocial caregiver intervention in three racial ethnic groups. J Gerontol B Psychol Sci 2010; 65: 185–94.
102. Gitlin LN, Winter L, Corcoran M, et al. Effects of the home environmental skill-building program on the caregiver-care recipient dyad: 6-month outcomes from the Philadelphia REACH project. Gerontologist 2003; 43: 532–46.
103. Schulz R, Lustig A, Handler S, et al. Technology-based caregiver intervention research: current status and future directions. Gerontechnology 2002; 2: 15–47.
104. Sorensen S, Pinquart M, Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. Gerontologist 2002; 42: 356–72.
105. Hall GR, Buckwalter KC. Progressively lowered stress threshold: a conceptual model for care of adults with Alzheimer's disease. Arch Psychiatr Nurs 1987; 1: 399–406
106. Gerdner LA, Buckwalter KC, et al. Impact of a psychoeducational intervention on caregiver responses to behavioral problems. Nurs Res 2002; 51: 363–74.
107. Lawton MP, Nahemow LE. Ecology and the aging process. In Eisdorfer C, Lawton MP, eds. The Psychology of Adults: Development and Aging. Washington DC: American Psychological Association, 1973; 619–74.
108. Gitlin LN, Corcoran M, Winter L, et al. A randomized, controlled trial of a home environmental intervention: effect of efficacy and upset in caregivers and on daily function of persons with dementia. Gerontologist 2001; 41: 4–14.
109. Brodaty H, Low LF. Agression in the elderly. J Clin Psychiatry 2003; 64(4): 36–43.
110. Landes AM, Sperry SD, Strauss ME, et al. Apathy in Alzheimer's disease. J Am Geriatr Soc 2001; 49: 1700–7.
111. Looman WJ, Noelker LS, Schur D, et al. Impact of family members on nurse assistants: what helps, what hurts. Am J Alzheimers Dis 2002; 17: 350–6.
112. Hoerster L, Hickey EM, Bourgeois MS. Effects of memory aids on conversations between nursing home residents with dementia and nursing assistants. Neuropsychol Rehabil 2001; 11: 399–427.
113. O'Shea E, Devane D, Murphy K, et al. Effectiveness of a structured education reminiscence-based programme for staff on the quality of life of residents with dementia in long-stay units: a study protocol for a cluster randomized trial. Trials 2011; 12: 41.
114. Livingston G, Johnston K, Katona C, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162: 1996–2021.
115. Spector A, Orrell M, Davies S, et al. Can reality orientation be rehabilitated? Development and piloting of an evidence-based programme of cognition-based therapies for people with dementia. Neuropsychol Rehabil 2001; 11: 377–97.
116. Breuil V, Rotrou JD, Forette F, et al. Cognitive stimulation of patients with dementia: preliminary results. Int J Geriatr Psychiatry 1994; 9: 211–17.
117. Westerberg K, Strandberg S. Showering is more than resistance: cognitive interview sequences in residential homes for elderly clients with dementia. Qual Res Psychol 2007; 4: 15–28.
118. Dunn JC, Thiru-Chelvan B, Beck CH. Bathing. Pleasure or pain? J Gerontol Nurs 2002; 28: 6–13.
119. Martin L, Rozon R, McDowell S, et al. Evaluation of a training program for long term care staff on bathing techniques for persons with dementia. Alzheim Care Q 2004; 5: 217–29.
120. Radar J, Lavelle M, Hoeffer B, et al. Maintaining cleanliness: an individualized approach. J Gerontol Nurs 1996; 22: 32–8.
121. Harris M, Richards KC. The physiological and psychological effects of slow-stroke back message on relaxation in older adults. J Clin Nurs 2010; 19: 914–26.
122. Suzuki M., Tatsumi A, Otsuka T, et al. Physical and physiological effects of a 6-week massage on elderly patients with severe dementia. Am J Alzheimers Dis 2010; 25: 680–6.
123. Vigen CLP, Mack WJ, Keefe RSW, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168: 831–9.
124. McClendon MJ, Smyth KA, Neundorfer MM. Survival of persons with Alzheimer's disease: caregiver coping matters. Gerontologist 2004; 44: 508–19.
125. Slone DG, Gleason CE. Behavior management planning for problem behaviors in dementia: a practical model. Prof Psychol Res 1999; 30: 27–36.
126. Quayhagen MP, Quayhagen M. Testing of a cognitive intervention for dementia caregiver dyads. Neuropsychol Rehabil 2001; 11: 319–32.
127. Neely AS, Vikstrom S, Josephsson S. Collaborative memory intervention in dementia: caregiver participation matters. Neuropsychol Rehabil 2009; 19: 695–715.
128. Nomura M, Makimoto K, Kato M, et al. Empowering older people with early dementia and family caregivers: a participatory action research study. Int J Nurs Stud 2009; 46: 431–41.
129. Thorgrimsen L, Schweitzer P, Orrell M. Evaluating reminiscence therapy for people with dementia: a pilot study. Arts Psychother 2002; 29: 93–7.
130. Woods R, Bruce E, Edwards R, et al. Reminiscence groups for people with dementia and their family carers: pragmatic eight-centre randomized trial of joint reminiscence and maintenance versus usual treatment: a protocol. Trials 2009 10: 64.
131. Woods B, Spector A, Jones C, et al. Reminiscence therapy for dementia. Cochrane Database Syst Rev 2005: 2: CD001120.
132. Gerdner L. Use of individualized music by trained staff and family. J Gerontol Nurs 2005; 31: 22–30.
133. Gerdner L. An individualized music intervention for agitation. J Am Psychiatry Nurs Assoc 1997; 3: 177–84.
134. Gitlin LN, Winter L, Dennis MP, et al. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers. The COPE randomized trial. JAMA 2010; 304: 983–91.
135. Gitlin LN, Winter L, Dennis MP, et al. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc 2010; 58: 1465–75.
136. Phinney A, Chaudlhury H, O'Connor DL. Doing as much as I can do: the meaning of activity for people with dementia. Aging Ment Health 2007; 11: 384–93.
137. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: randomized controlled trial. JAMA 2003; 290: 2015–22
138. Teri L, Logsdon RG, Uomoto J, et al. Behavioral treatment of depression in dementia. A controlled clinical trial. J Gerontol B Psychol Sci 1997; 52: P159–66,
139. Brooker DJ, Woolley RJ, Lee D. Enriching opportunities for people living with dementia: the development of a blueprint for a sustainable activity-based model. Aging Ment Health 2007; 11: 371–83.
140. Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomized trial. BMJ 2006; 332: 756–61.
141. Kolanowski AM, Buettner L. Prescribing activities that engage passive residents. an innovative method. J Gerontol Nurs 2008; 34: 13–18.
142. Gitlin LN, Winter L, Burke J, et al. Tailored activities to manage neuropsychiatric behaviors in persons with dementia and reduce caregiver burden: a randomized pilot study. Am J Geriatr Psychiatry 2008; 16: 229–39.
143. Gaugler JE, Roth DL, Haley WE, et al. Can counselling and support reduce burden and depressive symptoms in caregivers of people with Alzheimer's disease during the transition to institutionalization? Results from the New York University caregiver intervention study. J Am Geriatr Soc 2008; 56: 421–8.
144. Mittleman MS, Haley WE, Clay OJ, et al. Improving caregiver well-being delays nursing home placement of patients with Alzheimer's disease. Neurology 2006; 67: 1592–9.
145. Machii K, Cohen D, Ramos-Estebanez C, et al. Safety of rTMS to non-motor cortex areas in healthy participants and patients. Clin Neurophysiol 2006; 117: 455–71.
146. Luber B, Kinnunen LH, Rakitin BC, et al. Facilitation of performance in a working memory task with rTMS stimulation of the percuneus: frequency- and time-dependent effects. Brain Res 2007; 1128: 120–9.
147. Naeser MA, Martin PI, Nicholas M, et al. Improved picture naming in chronic aphasia after TMs to part of right Broca's area: an open protocol study. Brain Lang 2005; 93: 95–105.
148. Sole-Padulles C, Bartres-Faz D, Junque C, et al. Repetitive transcranial magnetic stimulation effects on brain function and cognition among elders with memory dysfunction. A randomized sham controlled study. Cereb Cortex 2006; 16: 1487–93.
149. Fregni F, Boggio PS, Nitche M, et al. Anodal transcranial direct current stimulation of prefrontal cortex enhances working memory. Exp Brain Res 2005; 166: 23–30.
150. Iyer MB, Mattu U, Lomarey M, et al. Safety and cognitive effect of frontal DC brain polarization in healthy individuals. Neurology 2005; 8: 872–5.
151. Nitshe MA, Fricke K, Henschke U, et al. Pharmacological modulation of cortical excitability shifts induced by transcranial direct current stimulation in humans. J Physiol 2003; 553: 293–301.
152. Marshall L, Helgadottir H, Molle M, et al. Boosting slow oscillations during sleep potentiates memory. Nature 2006; 444: 610–13.
153. Hamani C, McAndrews MP, Cohn M, et al. Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol 2008; 63: 119–23.
154. Laxton AW, Tang-Wai DF, McAndrews MP, et al. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol 2010; 68: 521–34.
155. Jiang F, Racine R, Turnbull J. Electrical stimulation of the septal region of aged rats improves performance in an open-field maze. Physiol Behav 1997; 62: 1279–82.
156. McNaughton N, Ruan M, Woodnorth MA. Restoring theta-like rhythmicity in rats in the Morris water maze. Hippocampus 2006; 16: 1102–10.
157. Fried I, Suthana NA, Haneef A, et al. Deep brain stimulation of the human entorhinal cortex region enhances memory. Am Assoc Neurol Surgeons 2011; 801.
158. Cerf M, Thiruvengadam N, Mormann F, et al. On-line, voluntary control of human temporal lobe neurons. Nature 2010; 467: 1104–8.
159. Zhang J, Laiwalla F, Kim JA, et al. Integrated device for optical stimulation and spatiotemporal electrical recording of neural activity in light-sensitized brain tissue. J Neural Eng 2009; 6: 055007.
160. Pfister BJ, Huang JH, Kameswaran N, et al. Neural engineering to produce in vitro nerve constructs and neurointerface. Neurosurgery 2007; 60: 137–41.
161. Rebesco JM, Stevenson IH, Kording KP, et al. Rewiring neural interactions by micro-stimulation. Front Syst Neurosci 2010; 39: 4: 1–15.
162. Arthur JV, Boahen K. Learning in silicon: timing is everything. In Scholkopf B, Weiss Y, eds. Advances in Neural Information Processing Systems 18. Cambridge, MA: MIT Press, 2006; 75–82.
163. Berger TW, Ahuja A, Courellis SH, et al Restoring lost cognitive function. IEEE Eng Med Biol Mag 2005; 24: 30–44.
164. Ji D, Wilson MA. Coordinated memory replay in the visual cortex and hippocampus during sleep. Nat Neurosci 2007; 10: 100–7.
165. Moriarity JL, Boatman D, Krauss GL, et al. Human “memories” can be evoked by stimulation of the lateral temporal cortex after ipsilateral medial temporal lobe resection. J Neurol Neurosur Psychiatry 2001; 71: 49–51.
166. Penfield W, Perot P. The brain's record of auditory and visual experience: a final summary and discussion. Brain 1963; 86: 595–696.
167. Bretelier MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153–60.
168. Cooper JL. Dietary lipids in the aetiology of Alzheimer's disease: implication for therapy. Drugs Aging 2003; 20: 399–418.
169. DeCarli C. The role of cerebrovascular diasease in dementia. Neurologist 2003; 9: 123–36.
170. Garcia A, Zanibbi K. Homocysteine and cognitive function in elderly people. Can Med Assoc J 2004; 171: 897–904.
171. Grossman H. Does diabetes protect or provoke Alzheimer's disease? Insights in the pathobiology and future treatment of Alzheimer's disease. CNS Spectr 2003; 8: 815–23.
172. Haan MN, Wallace R. Can dementia be prevented? Brain aging in a population-based context. Annu Rev Publ Health 2004; 25: 1–14.
173. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 2003; 34: 335–7.
174. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004; 3: 579–87.
175. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Arterioscler Rep 2004; 6: 261–6.
176. Mayeux R. Alzheimer's disease: epidemiology. Hand Clin Neurol 2008; 89: 195–205.
177. Messier C. Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol 2003; 38: 941–6.
178. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 2003; 72: 141–6.
179. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarct which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res 2003; 25: 605–10.
180. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 2: 425–8.
181. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003; 9: 94–101.
182. Qiu C, DeRonchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380–5.
183. Refolo LM, Fillit HM. Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer's disease. J Mol Neurosci 2004; 23: 151–5.
184. Rocchi A, Pellegrini S, Siciliano G, et al. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull 2003; 61: 1–24.
185. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 2003; 51: S296–304.
186. Roman GC, Erkinjuntti T, Wallin A, et al. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1: 426–36.
187. Saykin AJ, Wishart HA. Mild cognitive impairment: conceptual issues and structural and functional brain correlates. Semin Clin Neuropsychiatry 2003; 8: 12–30.
188. Scarmeas N, Stern Y. Cognitive reserve and lifestyle. J Clin Exp Neuropsychol 2003; 25: 625–633.
189. Schraen-Maschke S, Dhaenens CM, Delacourte A, et al. Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases. Neurobiol Dis 2004; 15: 449–60.
190. Skoog I, Gustafson D. Hypertension, hypertensive-clustering factors and Alzheimer's disease. Neurol Res 2003; 25: 675–80.
191. Solfrizzi V, Panza F, Capurso A. The role of diet in cognitive decline. J Neural Transm 2003; 110: 95–110.
192. Townsend KP, Obregon D, Quadros A, et al. Proinflammatory and vasoactive effects of A-beta in the cerebrovasculature. Ann N Y Acad Sci 2002; 977: 65–76.
193. Wakutani Y, Kowa H, Kusumi M. et al. Genetic analysis of vascular factors in Alzheimer's disease. Ann N Y Acad Sci 2002; 977: 232–8.
194. Wang X-P, Ding H-L. Alzheimer's disease: epidemiology, genetics and beyond. Neurosci Bull 2008; 24: 105–9.
195. Youssef FF, Addae JI. Learning may provide neuroprotection against dementia. W Indian Med J 2002; 51: 143–7.
196. Clare L, Woods B. Editorial: a role for cognitive rehabilitation in dementia care. Neuropsychol Rehabil 2001; 11: 193–6.

References

1. Brown AW, Elovic EP, Kothari S, et al. Congenital and acquired brain injury. 1. Epidemiology, pathophysiology, prognostication, innovative treatments, and prevention. Arch Phys Med Rehabil 2008; 89: S3–8.
2. Summers CR, Ivins B, Schwab KA. Traumatic brain injury in the United States: an epidemiologic overview. Mt Sinai J Med 2009; 76: 105–10.
3. Corrigan JD, Selassie AW, Orman JA. The epidemiology of traumatic brain injury. J Head Trauma Rehabil 2010; 25: 72–80.
4. DePalma RG, Burris DG, Champion HR, et al. Blast injuries. N Engl J Med 2005; 352: 1335–42.
5. Martin EM, Lu WC, Helmick K, et al. Traumatic brain injuries sustained in the Afghanistan and Iraq wars. Am J Nurs 2008; 108: 40–7.
6. Dardiotis E, Fountas KN, Dardioti M, et al. Genetic association studies in patients with traumatic brain injury. Neurosurg Focus 2010; 28: E9.
7. Jordan BD. Genetic influences on outcome following traumatic brain injury. Neurochem Res 2007; 32: 905–15.
8. Pelinka LE, Kroepfl A, Leixnering M, et al. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 2004; 21: 1553–61.
9. Berger RP, Adelson PD, Pierce MC, et al. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 2005; 103: 61–8.
10. Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 1998; 273: 22490–7.
11. Svetlov SI, Larner SF, Kirk DR, et al. Biomarkers of blast-induced neurotrauma: profiling molecular and cellular mechanisms of blast brain injury. J Neurotrauma 2009; 26: 913–21.
12. Bazarian JJ, Blyth B, Cimpello L. Bench to bedside: evidence for brain injury after concussion–looking beyond the computed tomography scan. Acad Emerg Med 2006; 13: 199–214.
13. Dubroff JG, Newberg A. Neuroimaging of traumatic brain injury. Semin Neurol 2008; 28: 548–57.
14. De Coene B, Hajnal JV, Pennock JM, et al. MRI of the brain stem using fluid attenuated inversion recivery pulse sequences. Neuroradiology 1993; 35: 327–31.
15. Haacke EM, Mittal S, Wu Z, et al. Susceptibility-weighted imaging: technical aspects and clinical applications, Part 1. Am J Neuroradiol 2009; 30: 19–30.
16. Kou Z, Wu Z, Tong KA, et al. The role of advanced MR imaging findings as biomarkers of traumatic brain injury. J Head Trauma Rehabil 2010; 25: 267–82.
17. Tong KA, Ashwal S, Holshouser BA, et al. Hemorrhagic shearing lesions in children and adolescents with posttraumatic diffuse axonal injury: improved detection and initial results. Radiology 2003; 227: 332–9.
18. Wu Z, Li S, Lei J, et al. Evaluation of traumatic subarachnoid hemorrhage using susceptibility-weighted imaging. Am J Neuroradiol 2010; 31: 1302–10.
19. Ptak T, Sheridan RL, Rhea JT, et al. Cerebral fractional anisotropy score in trauma patients: a new indicator of white matter injury after trauma. Am J Roentgenol 2003; 181: 1401–7.
20. Ross BD, Ernst T, Kreis R, et al. 1H MRS in acute traumatic brain injury. J Magn Reson Imaging 1998; 8: 829–40.
21. Garnett MR, Blamire AM, Rajagopalan B, et al. Evidence for cellular damage in normal-appearing white matter correlates with injury severity in patients following traumatic brain injury: a magnetic resonance spectroscopy study. Brain 2000; 123: 1403–9.
22. Garnett MR, Corkill RG, Blamire AM, et al. Altered cellular metabolism following traumatic brain injury: a magnetic resonance spectroscopy study. J Neurotrauma 2001; 18: 231–40.
23. Ashwal S, Holshouser BA, Tong KA. Use of advanced neuroimaging techniques in the evaluation of pediatric traumatic brain injury. Dev Neurosci 2006; 28: 309–26.
24. Makoroff KL, Cecil KM, Care M, et al. Elevated lactate as an early marker of brain injury in inflicted traumatic brain injury. Pediatr Radiol 2005; 35: 668–76.
25. Alavi A, Mirot A, Newberg A, et al. Fluorine-18-FDG evaluation of crossed cerebellar diaschisis in head injury. J Nucl Med 1997; 38: 1717–20.
26. Teasdale GM, Murray GD, Nicoll JA. The association between APOE epsilon4, age and outcome after head injury: a prospective cohort study. Brain 2005; 128: 2556–61.
27. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39: 19–52.
28. Ariza M, Matarin MD, Junque C, et al. Influence of angiotensin-converting enzyme polymorphism on neuropsychological subacute performance in moderate and severe traumatic brain injury. J Neuropsychiatry Clin Neurosci 2006; 18: 39–44.
29. Martinez-Lucas P, Moreno-Cuesta J, Garcia-Olmo DC, et al. Relationship between the Arg72Pro polymorphism of p53 and outcome for patients with traumatic brain injury. Intensive Care Med 2005; 31: 1168–73.
30. Uzan M, Tanriverdi T, Baykara O, et al. Association between interleukin-1 beta (IL-1beta) gene polymorphism and outcome after head injury: an early report. Acta Neurochir 2005; 147: 715–20.
31. Hadjigeorgiou GM, Paterakis K, Dardiotis E, et al. IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury. Neurology 2005; 65: 1077–82.
32. Chiaretti A, Antonelli A, Mastrangelo A, et al. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma 2008; 25: 225–34.
33. Chew E, Zafonte RD. Pharmacological management of neurobehavioral disorders following traumatic brain injury–a state-of-the-art review. J Rehabil Res Dev 2009; 46: 851–79.
34. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med 2001; 344: 556–63.
35. Clifton GL, Choi SC, Miller ER, et al. Intercenter variance in clinical trials of head trauma–experience of the National Acute Brain Injury Study: Hypothermia. J Neurosurg 2001; 95: 751–5.
36. Hutchison JS, Ward RE, Lacroix J, et al. Hypothermia therapy after traumatic brain injury in children. N Engl J Med 2008; 358: 2447–56.
37. Talving P, Lustenberger T, Kobayashi L, et al. Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. Ann Surg 2010; 251: 1–4.
38. Stahel PF, Flierl MA. Erythropoietin in traumatic brain injury: the “golden bullet” on the horizon? Neurol India 2009; 57: 693–4.
39. Lu D, Mahmood A, Qu C, et al. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma 2005; 22: 1011–17.
40. Mammis A, McIntosh TK, Maniker AH. Erythropoietin as a neuroprotective agent in traumatic brain injury: review. Surg Neurol 2009; 71: 527–31.
41. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med 2007; 49: 391–402.
42. Zafonte R, Friedewald WT, Lee SM, et al. The citicoline brain injury treatment (COBRIT) trial: design and methods. J Neurotrauma 2009; 26: 2207–16.
43. Dempsey RJ, Raghavendra Rao VL. Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. J Neurosurg 2003; 98: 867–73.
44. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002; 33: 2850–7.
45. Yurkewicz L, Weaver J, Bullock MR, et al. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma 2005; 22: 1428–43.
46. Maas AI, Murray G, Henney H, et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006; 5: 38–45.
47. Martin RT, Whyte J. The effects of methylphenidate on command following and yes/no communication in persons with severe disorders of consciousness: a meta-analysis of n-of-1 studies. Am J Phys Med Rehabil 2007; 86: 613–20.
48. Meythaler JM, Brunner RC, Johnson A, et al. Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. J Head Trauma Rehabil 2002; 17: 300–13.
49. Hughes S, Colantonio A, Santaguida PL, et al. Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury. Brain Inj 2005; 19: 1197–206.
50. Patrick PD, Blackman JA, Mabry JL, et al. Dopamine agonist therapy in low-response children following traumatic brain injury. J Child Neurol 2006; 21: 879–85.
51. Teitelman E. Off-label uses of modafinil. Am J Psychiatry 2001; 158: 1341.
52. Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil 2008; 23: 52–63.
53. Gualtieri CT, Evans RW. Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury. Brain Inj 1988; 2: 273–90.
54. Plenger PM, Dixon CE, Castillo RM, et al. Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. Arch Phys Med Rehabil 1996; 77: 536–40.
55. Whyte J, Hart T, Vaccaro M, et al. Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. Am J Phys Med Rehabil 2004; 83: 401–20.
56. Reid WM, Hamm RJ. Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury. J Neurotrauma 2008; 25: 248–56.
57. Ripley DL. Atomoxetine for individuals with traumatic brain injury. J Head Trauma Rehabil 2006; 21: 85–8.
58. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci 1997; 9: 222–30.
59. Levin HS, Peters BH, Kalisky Z, et al. Effects of oral physostigmine and lecithin on memory and attention in closed head-injured patients. Cent Nerv Syst Trauma 1986; 3: 333–42.
60. Cardenas DD, McLean A, Farrell-Roberts L, et al. Oral physostigmine and impaired memory in adults with brain injury. Brain Inj 1994; 8: 579–87.
61. Silver JM, Koumaras B, Chen M, et al. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology 2006; 67: 748–55.
62. Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004; 85: 1050–5.
63. Riggio S, Wong M. Neurobehavioral sequelae of traumatic brain injury. Mt Sinai J Med 2009; 76: 163–72.
64. Lieberman SA, Oberoi AL, Gilkison CR, et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J Clin Endocr Metab 2001; 86: 2752–6.
65. Bondanelli M, De Marinis L, Ambrosio MR, et al. Occurrence of pituitary dysfunction following traumatic brain injury. J Neurotrauma 2004; 21: 685–96.
66. Schneider M, Schneider HJ, Stalla GK. Anterior pituitary hormone abnormalities following traumatic brain injury. J Neurotrauma 2005; 22: 937–46.
67. Ceballos R. Pituitary changes in head trauma (analysis of 102 consecutive cases of head injury). Ala J Med Sci 1966; 3: 185–98.
68. Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993; 34: 216–22.
69. Daniel PM, Prichard MM, Treip CS. Traumatic infarction of the anterior lobe of the pituitary gland. Lancet 1959; 2: 927–31.
70. Kornblum RN, Fisher RS. Pituitary lesions in craniocerebral injuries. Arch Path Lab Med 1969; 88: 242–8.
71. Popovic V, Pekic S, Pavlovic D, et al. Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. J Endocrinol Invest 2004; 27: 1048–54.
72. Aimaretti G, Ambrosio MR, Benvenga S, et al. Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). Growth Horm IGF Res 2004; 14: S114–17.
73. Kelly DF, Gonzalo IT, Cohan P, et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. J Neurosurg 2000; 93: 743–52.
74. Benvenga S, Campenni A, Ruggeri RM, et al. Clinical review 113: hypopituitarism secondary to head trauma. J Clin Endocrinol Metab 2000; 85: 1353–61.
75. Casanueva FF, Leal A, Koltowska-Haggstrom M, et al. Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: a KIMS-based study. Arch Phys Med Rehabil 2005; 86: 463–8.
76. Agha A, Phillips J, O'Kelly P, et al. The natural history of post-traumatic hypopituitarism: implications for assessment and treatment. Am J Med 2005; 118: 1416.
77. Agha A, Thornton E, O'Kelly P, et al. Posterior pituitary dysfunction after traumatic brain injury. J Clin Endocrinol Metab 2004; 89: 5987–92.
78. Bavisetty S, McArthur DL, Dusick JR, et al. Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome. Neurosurgery 2008; 62: 1080–93.
79. Park KD, Kim DY, Lee JK, et al. Anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury patients and the influence on functional outcome. Brain Inj 2010; 24: 1330–5.
80. High WM, Briones-Galang M, Clark JA, et al. Effect of growth hormone replacement therapy on cognition after traumatic brain injury. J Neurotrauma 2010; 27: 1565–75.
81. Springer J, Chollet A. A traumatic car crash. Lancet 2001; 357: 1848.
82. Ghigo E, Masel B, Aimaretti G, et al. Consensus guidelines on screening for hypopituitarism following traumatic brain injury. Brain Inj 2005; 19: 711–24.
83. Katz RT, Brander V, Sahgal V. Updates on the diagnosis and management of posttraumatic hydrocephalus. Am J Phys Med Rehabil 1989; 68: 91–6.
84. Zasler NKD, Zafonte R. Brain Injury Medicine: Principles and Practice. New York, NY: Demos, 2007.
85. Aminoff MGD, Simon R. Clinical Neurology. New York, NY: McGraw-Hill, 2005.
86. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71: 576–86.
87. Yablon SA. Posttraumatic seizures. Arch Phys Med Rehabil 1993; 74: 983–1001.
88. Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery 1990; 27: 1–11.
89. Payan H, Toga M, Berard-Badier M. The pathology of post-traumatic epilepsies. Epilepsia 1970; 11: 81–94.
90. Agrawal A, Timothy J, Pandit L, et al. Post-traumatic epilepsy: an overview. Clin Neurol Neurosurg 2006; 108: 433–9.
91. Temkin NR. Risk factors for posttraumatic seizures in adults. Epilepsia 2003; 44: 18–20.
92. Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256–62.
93. Annegers JF, Grabow JD, Groover RV, et al. Seizures after head trauma: a population study. Neurology 1980; 30: 683–9.
94. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001; 42: 515–24.
95. Chang BS, Lowenstein DH. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 60: 10–16.
96. Dikmen SS, Temkin NR, Miller B, et al. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991; 265: 1271–7.
97. Perna R. Brain injury: benzodiazepines, antipsychotics, and functional recovery. J Head Trauma Rehabil 2006; 21: 82–4.
98. Young RR. Spasticity: a review. Neurology 1994; 44: S12–20.
99. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206–7.
100. Ansari NN, Naghdi S, Hasson S, et al. The Modified Tardieu Scale for the measurement of elbow flexor spasticity in adult patients with hemiplegia. Brain Inj 2008; 22: 1007–12.
101. Rekand T. Clinical assessment and management of spasticity: a review. Acta Neurol Scand 2010; 190: 62–6.
102. Tan J. Practice Manual of Physical Medicine and Rehabilitation. St Louis, MO: Mosby, 1998.
103. Kaplan FS, Glaser DL, Hebela N, et al. Heterotopic ossification. J Am Acad Orthop Surg 2004; 12: 116–25.
104. Watanabe TKSM. Common medical complications of traumatic brain injury. Phys Med Rehabil 2001; 15: 283–99.
105. Van den Bossche L, Van der Straeten G. Heterotopic ossification: a review. J Rehabil Med 2005; 37: 129–36.
106. Blackman JA, Patrick PD, Buck ML, et al. Paroxysmal autonomic instability with dystonia after brain injury. Arch Neurol 2004; 61: 321–8.
107. Baguley IJ, Cameron ID, Green AM, et al. Pharmacological management of dysautonomia following traumatic brain injury. Brain Inj 2004; 18: 409–17.
108. Bullard DE. Diencephalic seizures: responsiveness to bromocriptine and morphine. Ann Neurol 1987; 21: 609–11.
109. Wang VY, Manley G. Recognition of paroxysmal autonomic instability with dystonia (PAID) in a patient with traumatic brain injury. J Trauma 2008; 64: 500–2.
110. McAllister TW. Neurobehavioral sequelae of traumatic brain injury: evaluation and management. World Psychiatry 2008; 7: 3–10.
111. Tsaousides T, Gordon WA. Cognitive rehabilitation following traumatic brain injury: assessment to treatment. Mt Sinai J Med 2009; 76: 173–81.
112. McCrea M, Guskiewicz KM, Marshall SW, et al. Acute effects and recovery time following concussion in collegiate football players: the NCAA concussion study. JAMA 2003; 290: 2556–63.
113. Ruttan L, Martin K, Liu A, et al. Long-term cognitive outcome in moderate to severe traumatic brain injury: a meta-analysis examining timed and untimed tests at 1 and 4.5 or more years after injury. Arch Phys Med Rehabil 2008; 89: S69–76.
114. Sandel ME, Mysiw WJ. The agitated brain injured patient. Part 1: Definitions, differential diagnosis, and assessment. Arch Phys Med Rehabil 1996; 77: 617–23.
115. Nott MT, Chapparo C, Baguley IJ. Agitation following traumatic brain injury: an Australian sample. Brain Inj 2006; 20: 1175–82.
116. Rogers JM, Read CA. Psychiatric comorbidity following traumatic brain injury. Brain Inj 2007; 21: 1321–33.
117. Whelan-Goodinson R, Ponsford J, Johnston L, et al. Psychiatric disorders following traumatic brain injury: their nature and frequency. J Head Trauma Rehabil 2009; 24: 324–32.
118. Simpson G, Tate R. Suicidality in people surviving a traumatic brain injury: prevalence, risk factors and implications for clinical management. Brain Inj 2007; 21: 1335–51.
119. King NS. PTSD and traumatic brain injury: folklore and fact? Brain Inj 2008; 22: 1–5.
120. van Reekum R, Cohen T, Wong J. Can traumatic brain injury cause psychiatric disorders? J Neuropsychiatry Clin Neurosci 2000; 12: 316–27.
121. Minderhoud JM, Boelens ME, Huizenga J, et al. Treatment of minor head injuries. Clin Neurol Neurosurg 1980; 82: 127–40.
122. Baandrup L, Jensen R. Chronic post-traumatic headache–a clinical analysis in relation to the International Headache Classification, 2nd edition. Cephalalgia 2005; 25: 132–8.
123. Evans RW. Post-traumatic headaches. Neurol Clin 2004; 22: 237–49.
124. Packard RC. Epidemiology and pathogenesis of posttraumatic headache. J Head Trauma Rehabil 1999; 14: 9–21.
125. Bushnik T, Englander J, Wright J. The experience of fatigue in the first 2 years after moderate-to-severe traumatic brain injury: a preliminary report. J Head Trauma Rehabil 2008; 23: 17–24.
126. Ouellet MC, Savard J, Morin CM. Insomnia following traumatic brain injury: a review. Neurorehabil Neural Repair 2004; 18: 187–98.
127. Chen H, Epstein J, Stern E. Neural plasticity after acquired brain injury: evidence from functional neuroimaging. PM R 2010; 2: S306–12.
128. Weiller C, Chollet F, Friston KJ, et al. Functional reorganization of the brain in recovery from striatocapsular infarction in man. Ann Neurol 1992; 31: 463–72.
129. Werring DJ, Clark CA, Barker GJ, et al. The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in a traumatic injury of the internal capsule. J Neurol Neurosurg Psychiatry 1998; 65: 863–9.
130. Nakamura T, Hillary FG, Biswal BB. Resting network plasticity following brain injury. PloS One 2009; 4: e8220.
131. Ween JE. Functional imaging of stroke recovery: an ecological review from a neural network perspective with an emphasis on motor systems. J Neuroimaging 2008; 18: 227–36.
132. Swaine BR, Sullivan SJ. Longitudinal profile of early motor recovery following severe traumatic brain injury. Brain Inj 1996; 10: 347–66.
133. Page S, Levine P. Forced use after TBI: promoting plasticity and function through practice. Brain Inj 2003; 17: 675–84.
134. Page SJ, Yablon S. Plasticity in TBI: concepts and applications. Brain Inj 2003; 17: 639–41.

References

1. Morrell F, Whisler WW, Smith MC, et al. Landau-Kleffner Syndrome: a treatment with subpial transcortical transections. Brain 1995; 118: 1529–46.
2. Vickrey BG, Hays RD, Graber J, et al. A health related quality of life instrument for patients evaluated for epilepsy surgery. Med Care 1992; 30: 299–319.
3. Stavem K, Bjornaes H, Lossius MI. Reliability and validity of a Norwegian version of the quality of life in epilepsy inventory (QOLIE-89). Epilepsia 2000; 41: 91–7.
4. Vickrey BG, Hays RD, Rausch R, et al. Outcomes in 248 patients who had diagnostic evaluations for epilepsy surgery. Lancet 1995; 346: 1445–9.
5. Meador KJ. (1993). Research use of the new quality-of-life in epilepsy inventory. Epilepsia 1993; 34: S34–8.
6. Sillanpaa M, Jalava M, Kaleva D, et al. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998; 338: 1715–22.
7. Camfield C, Camfield P. Social outcome of children with epilepsy and normal intelligence: long-term follow-up of a population based cohort. In Tuxhorn I, Holthausen H, Boenigk H, eds. Pediatric Epilepsy Syndromes and their Surgical Treatment. John Libbey: London, 1997; 44–7.
8. Sillanpaa M. Social adjustment and functioning of chronically ill and impaired children and adolescents. Acta Paediatr Scand 1987; 340: 1–70.
9. Schachter SC, Shafer PO, Murphy W. The personal impact of seizures: correlations with seizure frequency, employment, cost of medical care, and satisfaction with physician care. J Epilepsy 1993; 6: 224–7.
10. Austin JK, Risinger MW, Beckett LA. Correlates of behavior problems in children with epilepsy. Epilepsia 1992; 33: 1115–22.
11. Hoare P, Kerley S. Psychosocial adjustment of children with chronic epilepsy and their families. Dev Med Child Neurol 1991; 33: 201–15.
12. Austin JK, Smith MS, Risinger MW, et al. Childhood epilepsy and asthma: comparison of quality of life. Epilepsia 1994; 35: 608–15.
13. Margalit M, Heiman T. Anxiety and self-dissatisfaction in epileptic children. Int J Soc Psychiatr 1983; 29: 220–4.
14. Matthews WS, Barabas G, Ferrari M. Emotional concomitants of childhood epilepsy. Epilepsia 1982; 23: 671–81.
15. Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007; 48: 2336–44.
16. Perrine K, Hermann BP, Meador KJ, et al. The relationship of neuropsychological functioning to quality of life in epilepsy. Arch Neurol 1995; 52: 997–1003.
17. Lehrner J, Kalchmayr R, Serles R, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure 1999; 8: 88–92.
18. Gilliam F, Kuzniecky R, Meador K, et al. Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy. Neurology 1999; 53: 687–94.
19. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 2002; 58: S9–19.
20. Kanner AM, Barry JJ, Gilliam F, et al. Anxiety disorders, sub-syndromic depressive episodes and major depressive episodes: do they differ on their impact on the quality of life of patients with epilepsy? Epilepsia 2010; 51: 1152–8.
21. Devinsky O, Westbrook L, Cramer J, et al. Risk factors for poor health-related quality of life in adolescents with epilepsy. Epilepsia 1990; 40: 1715–20.
22. Dodrill CB. Neuropsychological effects of seizures. Epilepsy Behav 2004; 5:S21–4.
23. Bolton PF, Park RJ, Higgins JN, et al. Neuroepileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain 2002; 125: 1247–55.
24. Dodrill CB, Wilensky AJ. Intellectual impairment as an outcome of status epilepticus. Neurology 1990; 40: 23–7.
25. Dodrill CB. Progressive cognitive decline in adolescents and adults with epilepsy. Prog Brain Res 2002; 135: 399–407.
26. Aarts JHP, Binnie CD, Smit AM, et al. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain 1984; 107: 293–308.
27. Binnie C.D. Seizures, EEG discharges and cognition. In Trimble MR, Reynolds EH, eds. Epilepsy, Behavior and Cognitive Function. New York, NY: Wylie, 1987; 45–51.
28. Kateleijn-Nolst Trenite DGA, Smit AM, Velis DN, et al. On-line detection of transient neuropsychological disturbances during EEG discharges in children with epilepsy. Dev Med Child Neurol 1990; 32: 46–50.
29. Meador KJ, Loring DW, Allen ME, et al. Comparative of carbamazepine and phenytoin in healthy adults. Neurology 1991; 41: 1537–40.
30. Meador KJ, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993; 34: 153–7.
31. Meador KJ, Loring DW, Moore EE, et al. Comparative cognitive effects of carbamazepine and phenytoin, and valproate in healthy adults. Neurology 1995; 45: 1494–9.
32. Vining EPG, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80: 165–74.
33. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 1990; 52: 321–7.
34. Kanner AM, Barry JJ, Gilliam F, et al. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia 2012; 53: 1104–8.
35. Lewis A. Melancholia: a historical review. J Mental Sci 1934; 80: 1–42.
36. Jacoby A, Baker GA, Steen N, et al, The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia 1996; 37: 148–61.
37. O'Donoghue MF, Goodridge DM, Redhead K, et al. Assessing the psychosocial consequences of epilepsy: a community-based study. Br J Gen Pract 1999; 49: 211–14.
38. Edeh J, Toone B. Relationship between interictal psychopathology and the type of epilepsy. Results of a survey in general practice. Br J Psychiatry 1987; 151: 95–101.
39. Rutter M, Graham P, Yule WA. Neuropsychiatric Study in Childhood. Philadelphia, PA: J. B. Lippincott Co, 1970.
40. McDermott S, Mani S, Krishnaswami S. A population-based analysis of specific behavior problems associated with childhood seizures. J Epilepsy 1995; 8: 110–18.
41. Carlton-Ford S, Miller R, Brown M, et al. Epilepsy and children's social and psychological adjustment. J Health Soc Behav 1995; 36: 285–301.
42. Hempel AM, Frost MD, Ritter FJ, et al. Factors influencing the incidence of ADHD in pediatric epilepsy patients. Epilepsia 1995; 36: 122.
43. Semrud-Clikeman M, Wical B. Components of attention in children with complex partial seizures with and without ADHD. Epilepsia 1999; 40: 211–15.
44. Dunn D. Attention Deficit Disorder in Epilepsy In A Ettinger A, Kanner AM, eds. Psychiatric Issues in Epilepsy: A Practical Guide to Diagnosis and Treatment. Philadelphia, PA: Lippincott Williams and Wilkins, 2001.
45. Adelow C, Anderson T, Ahlbom A, et al. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012; 78: 396–401.
46. Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality and psychiatric disorders: a bidirectional association. Ann Neurol 2012; 72: 184–91.
47. McAfee AT, Chilcott KE, Johannes CB, et al. The incidence of first unprovoked seizure in pediatric patients with and without psychiatric diagnoses. Epilepsia 2007; 48: 1075–82.
48. Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004; 61: 731–6.
49. Jones JE, Watson R, Sheth J, et al. Psychiatric comorbidity in patients with epilepsy. Dev Med Child Neurol 2007; 49: 493–7.
50. Berg AT, Smith SN, Frobish D, et al. Special education needs of children with newly diagnosed epilepsy. Dev Med Child Neurol 2005; 47: 749–53.
51. Forsgren L, Nystrom L. An incident case referent study of epileptic seizures in adults. Epilepsy Res 1990; 6: 66–81.
52. Hesdorffer DC, Hauser WA, Annegers JF, et al. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000; 47: 246–9.
53. Hesdorffer DC, Hauser WA, Ludvigsson P, et al. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol 2006; 59: 35–41.
54. Alper KR, Schwartz KA, Kolts RL, et al. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62: 345–54.
55. Blanchet P, Frommer GP. Mood change preceding epileptic seizures. J Nerv Ment Dis 1986; 174: 471–6.
56. Williams D. The structure of emotions reflected in epileptic experiences. Brain 1956; 79: 29–67.
57. Vazquez B, Devinsky O. Epilepsy and anxiety. Epilepsy Behav 2003; 4: S20–5.
58. Trimble MR. Psychosis of Epilepsy. New York, NY: Raven Press, 1991.
59. Devinsky O, Kelly K, Porter RG, et al. Clinical and electroencephalographic features of simple partial seizures. Neurology 1988; 43: 1347–52.
60. Kanner AM, Soto A, Gross-Kanner HR. Prevalence and clinical characteristics of postictal psychiatric symptoms. Neurology 2004; 62: 708–13.
61. Onuma T, Adachi N, Ishida S, et al. Prevalence and annual incidence of psychosis in patients with epilepsy. Psychiatry Clin Neuros 1995; 49: S267–8.
62. Kanner AM, Stagno S, Kotagal P, et al. Postictal psychiatric events during prolonged video-electroencephalographic monitoring studies. Arch Neurol 1996; 53: 258–63.
63. Devinsky O, Abrahmson H, Alper K. et al. Postictal psychosis: a case control study of 20 patients and 150 controls. Epilepsy Res 1995; 20: 247–53.
64. Kanemoto K, Kawasaki J, Kawai J. Postictal psychosis: a comparison with acute interictal and chronic psychoses. Epilepsia 1996; 37: 551–6.
65. Logsdail SJ, Toone BK. Postictal psychosis. A clinical and phenomenological description. Br J Psychiatry 1988; 152: 246–52.
66. So NK, Savard G, Andermann F, et al. Acute postictal psychosis: a stereo-EEG study. Epilepsia 1990; 31: 188–93.
67. Kanner AM, Ostrovskaya A. Long-term significance of postictal psychotic episodes II. Are they predictive of interictal psychotic episodes? Epilepsy Behav 2008; 12: 154–6.
68. Anthony JC, Eaton WW, Henderson AS. Looking in the future of psychiatric etiology. Epidemiol Rev 1995; 17: 240–2.
69. Costello EJ. Developments in child psychiatric epidemiology. J Am Acad Child Adolesc Psychiatry 1989; 28: 836–41.
70. Kanner AM, Palac S. Depression in epilepsy: a common but often unrecognized comorbid malady. Epilepsy Behav 2000; 1: 37–51.
71. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1995; 51: 8–19.
72. Mendez MF, Cummings J, Benson D, et al. Depression in epilepsy. Significance and phenomenology. Arch Neurol 1986; 43: 766–70.
73. Wiegartz P, Siedenberg M, Woodard A, et al. Co-morbid psychiatric disorders in chronic epilepsy: recognition and etiology of depression. Neurology 1999; 53: 2–8.
74. Kanner AM, Kozak AM, Frey M. The use of sertraline in patients with epilepsy: is it safe? Epilepsy Behav 2000; 1: 100–5.
75. Kraepelin E. Psychiatrie. Leipzig: Johann Ambrosius Barth, 1923.
76. Bleuler E. Lehrbuch der Psychiatrie. 8th edn. Berlin: Springer, 1949.
77. Gastaut H, Morin G, Lesèvre N. Étude du comportement des épileptiques psychomoteurs dans l'intervalle de leurs crises: les troubles de l'activité globale et de la sociabilité. Ann Med Psychol 1955; 113: 1–27.
78. Blumer D, Altshuler LL. Affective disorders. In Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott–Raven, 1998; 2083–99.
79. Mula M, Jauch R, Cavanna A, et al. Clinical and psychopathological definition of the interictal dysphoric disorder of epilepsy. Epilepsia 2008; 49: 650–6.
80. Sherman EM, Slick DJ, Connolly MB, et al. ADHD, neurological correlates and health-related quality of life in severe pediatric epilepsy. Epilepsia 2007; 48: 1083–91.
81. Barkley RA. Attention-Deficit/Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd edn. New York, NY: Guilford, 2006.
82. Jacoby A. Felt versus enacted stigma: a concept revisited. Soc Sci Med 1994; 38: 269–74.
83. Scambler G, Hopkins A. Being epileptic: coming to terms with stigma. Sociol Health Ill 1986; 8: 26–43.
84. Gil-Nagel A, Garcia Damberre P. The social impact of epilepsy: keeping our patients in the closet. In Ettinger A, Kanner AM, eds. Psychiatric Issues in Epilepsy: A Practical Guide to Diagnosis and Treatment. Philadelphia, PA: Lippincott Williams and Wilkins, 2001; 289–96.
85. Edwards VE. Social problems confronting a person with epilepsy in modern society. Proc Aust Assoc Neurol 1974; 11: 239–43.
86. Baker GA, Brooks J, Buck D, et al. The stigma of epilepsy: a European perspective. Epilepsia 2000; 41: 98–104.
87. Trostle JA. Social aspects: stigma, beliefs and measurement. In Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, PA: Lippincott–Raven, 1997; 2183–9.
88. Gilliam F, Kuzniecky R, Faught E. Patient-validated content of epilepsy-specific quality of life measurement. Epilepsia 1997; 38: 233–6.
89. Fisher RS, Bortz JJ, Blum DE, et al. A pilot study of donepezil for memory problems in epilepsy. Epilepsy Behav 2001; 2: 330–4.
90. Chelune GL, Najm RI, Luders H, et al. Individual change after epilepsy surgery: practice effects and base rate information. Neuropsychology 1993; 1: 41–52.
91. Gilliam FG, Black KJ, Carter J, et al. Depression and Health Outcomes in Epilepsy: A Randomized Trial. Proc 61st Ann Meet Am Acad Neurol Seattle, WA, 2009.
92. Wiebe S, Blume WT, Girvin JP, et al. Effectiveness and efficiency of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345: 311–18.
93. Engel J, Wiebe J, French J, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy. Neurology 2003; 60: 538–47.
94. Burg AT. Understanding the delay before the epilepsy surgery: Who develops intractable epilepsy and when? CNS Spectr 2004; 2: 136–44.
95. Kanner AM, Byrne R, Chicharro A, et al. A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 2009; 72: 793–9.
96. Engel J, Van Nes P, Rasmussen TB, et al. Outcome with respect to epileptic seizures. In Engel J, ed. 2nd ed. New York, NY: Raven Press, 1993; 609–621.
97. Anhoury S, Brown RJ, Krishnamoorthy ES, et al. Psychiatric outcome after temporal lobectomy: a predictive study. Epilepsia 2000; 41: 1608–15.
98. Martin RC, Sawrie SM, Roth DL, et al. Individual memory change after anterior temporal lobectomy: a base rate analysis using registration based outcome methodology. Epilepsia 1998; 39: 1075–82.
99. Novelly RA, Augustine EA, Mattson RH, et al. Selective memory improvement and impairment in temporal lobectomy in epilepsy. Ann Neurol 1984; 15: 64–7.
100. Ojieman G, Dodrill CB. Verbal memory deficits after left temporal lobectomy for epilepsy. J Neurosurg 1985; 62: 101–7.
101. Rausch R, Crandal PH. Psychological status related to surgical control of temporal lobe seizures. Epilepsia 1982; 23: 191–202.
102. Saykin AJ, Gur RC, Sussman NM, et al. Memory before and after temporal lobectomy: effects of laterality and age of onset. Brain Cogn 1989; 9: 191–200.
103. Herman BP, Wyler AR, Somes G, et al. Declarative memory following anterior temporal lobectomy in humans. Behav Neurosci 1984; 108: 3–10.
104. Herman BP, Wyler AR, Somes G. Memory loss following left anterior temporal lobectomy is associated with hippocampal pathology and not extend of hippocampal resection. J Clin Exp Neurophysiol 1993; 6: 350.
105. Kneebone AC, Chelune GJ, Dinner D, et al. Use of intracarotid amobarbital procedure to predict material specific memory change following anterior temporal lobectomy. Epilepsia 1995; 36: 857–65.
106. Sass KJ, Westerveld M, Bachanan CP, et al. Degree of hippocampal neuron loss determines severity of verbal memory decrease after anteromesiotemporal lobectomy. Epilepsia 1994; 35: 1179–86.
107. Seidenberg M, Hermann B, Wyler AR, et al. Neuropsychological outcome following anterior temporal lobectomy in patients with and without the syndrome of mesial temporal epilepsy. Neuropsychology 1998; 22: 303–16.
108. Popovic EA, Fabinyi GCA, Brazenor GA, et al. Temporal lobectomy for epilepsy: complications in 200 patients. J Clin Neurosci 1995; 2: 238–44
109. Tillwally S, Kanner AM, Leurgans S, et al. Postsurgical psychiatric complications of temporal lobectomy: a study of risk factors. Neurology 2003; 60: A118.
110. Ring HA, Moriarity J, Trimble MR. A prospective study of the early postsurgical psychiatric associations of epilepsy surgery. J Neurol Neurosurg Psychiatry 1998; 64: 601–4.
111. Blumer D, Wakhlu S, Davies K, et al. Psychiatric outcome of temporal lobectomy for epilepsy: incidence and treatment of psychiatric complications. Epilepsia 1998; 39: 478–86.
112. Bruton CJ. The Neuropathology of Temporal Lobe Epilepsy. Oxford: Oxford University Press, 1988.
113. Sperling M, Saykin A, Roberts F, et al. Occupational outcome after temporal lobectomy for refractory epilepsy. Neurology 1995; 45: 970–6.
114. Augustine E, Novelly RA, Mattson RH, et al. Occupational adjustment following neurosurgical treatment of epilepsy. Ann Neurol 1984; 15: 68–72.
115. Reeves AL, So EL, Evans RW, et al. Factors associated with work outcome after anterior temporal lobectomy for intractable epilepsy. Epilepsia 1997; 38: 689–95.
116. Lendth M, Helmstaedter C, Elger CE. Pre-and postoperative socio-economic development of 151 patients with focal epilepsies. Epilepsia 1997; 38: 1330–7.
117. Williams KL, Roth DL, Kuzniecky R, et al. Psychosocial outcome following temporal lobe surgery. J Epilepsy 1994; 7: 144–51.
118. Katz A, Award IA, Kong AK, et al. Extent of resection in temporal lobectomy for epilepsy II: memory changes and neurological complications. Epilepsia 1989; 30: 763–71.

References

1. Schrag A. Epidemiology of movement disorders. In Jankovic JJ, Tolosa E. eds. Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002; 73–89.
2. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the Euro–Parkinson collaborative study. J Neurol Neurosurg Psychiatry 1997; 62: 10–15.
3. Muller J, Kiechl S, Wenning GK, et al. The prevalence of primary dystonia in the general community. Neurology 2002; 59: 941–3.
4. Louis ED, Ottman R, Hauser WA. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998; 13: 5–10.
5. Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Neurology 2000; 54: 1064–8.
6. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197–211.
7. Biskup S, Gerlag M, Kupsch A, et al. Genes associated with Parkinson syndrome. J Neurol 2008; 255: 8–17.
8. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–7.
9. Khan NL, Graham E, Critchley P, et al. Parkinson's disease: a phenotypic study of a large case series. Brain 2003; 126: 1279–92.
10. Van De Warrenburg BP, Lammens M, Luecking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001; 56: 555–7.
11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745–52.
12. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861–70.
13. Schrag A, Good CD, Miszkiel K. et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697–702.
14. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F] dopa metabolism in the striatum in Parkinson's disease. Brain 1996; 119: 2097–103.
15. Brooks DJ. Movement disorders. In Jankovic JJ, Tolosa E, eds. Functional Imaging in Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002; 610–31.
16. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334: 71–6.
17. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611–15.
18. Hoehn MM, Yahr MDP. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–42.
19. Muller J, Wenning GK, Jellinger K, et al. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. Neurology 2000; 55: 888–91.
20. Hely MA, Reid WGJ, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837–44.
21. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044–53.
22. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484–91.
23. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009; 15: S97–100.
24. Merola A, Zibetti M, Angrisano S, et al. Comparison of subthalamic nucleus deep brain stimulation and duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011; 26: 664–70.
25. Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 2011; 4: 587–98.
26. Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001; 56: 548–51.
27. Deusch G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896–908.
28. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002; 73: 529–34.
29. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99–102.
30. Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary essential tremor. Brain 1994; 117: 805–24.
31. Koller WC, Busenbark K, Miner K. The relationship of essential tremor to other movement disorders: report on 678 patients. Ann Neurol 1994; 35: 717–23.
32. Critchley M. Arteriosclerotic parkinsonism. Brain 1929; 52: 23–83.
33. Zijlmans JC, Daniel SE, Hughes AJ, et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord 2004; 9: 630–40.
34. Fitzgerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord 1989; 4: 249–60.
35. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19–28.
36. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–24.
37. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229–37.
38. Tolosa E, Valldeoriola F, Pastor P. Progressive supranuclear palsy. In Jankovic JJ, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2002; 73–89.
39. Gai WP, Power JH, Blumbergs PC, et al. Multiple-system atrophy: a new alpha-synuclein disease? Lancet 1998; 352: 547–8.
40. Wenning GK, Ben-Shlomo Y, Maglhaes M, et al. Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1995; 117: 835–45.
41. Weiner WJ, Singer C. Parkinson's disease and non-pharmacological treatment programs. J Am Geriatr Soc 1989; 37: 359–63.
42. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17: 156–66.
43. Ward CD. Rehabilitation in Parkinson's disease and parkinsonism. In Meara J, Koller WC, eds. Parkinson's Disease and Parkinsonism in the Elderly. Cambridge: Cambridge University Press, 2000; 165–84.
44. Keus SHJ, Munneke M, Nijkrake MJ, et al. Physical therapy in Parkinson's disease: evolution and future challenges. Mov Disord 2009; 1: 1–14.
45. Morris ME. Locomotor training in people with Parkinson disease. Phys Ther 2006; 86: 1426–35.
46. Farley B, Koshland GF. Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson's disease. Exp Brain Res 2005; 167: 462–7.
47. Ebersbach G, Ebersbach A, Edler D, et al. Comparing exercise in Parkinson's disease–the Berlin LSVT®BIG study. Mov Disord 2010; 12: 1902–8.
48. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59: 408–13.
49. Giladi N, McMahon D, Przedborski S, et al. Motor blocks in Parkinson's disease. Neurology 1992; 42: 333–9.
50. Marsden CD. The mysterious motor function of the basal ganglia: the Robert Wartenberg lecture. Neurology 1982; 32: 514–39.
51. Brotchie P, Iansek R, Horne MK. Motor function of the monkey globus pallidus. 1. Neuronal discharge and parameters of movement. Brain 1991; 114: 1667–83.
52. Georgiou N, Iansek R, Bradshaw J, et al. An evaluation of the role of internal cues in the pathogenesis of parkinsonian hypokinesia. Brain 1993; 116: 1575–87.
53. Bloem BR, Hausdorff JM, Visser JE, et al. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004; 19: 871–84.
54. Abbruzzese G, Berardelli A. Sensorimotor integration in movement disorders. Mov Disord 2003; 18: 231–40.
55. Klockgether T, Dichgans J. Visual control of arm movements in Parkinson's disease. Mov Disord 1994; 9: 48–56.
56. Klockgether T, Borutta M, Rapp H, et al. A defect of kinesthesia in Parkinson's disease. Mov Disord 1995; 10: 460–5.
57. Moore AP. Impaired sensorimotor integration in parkinsonism and dyskinesias: a role of corollary discharges? J Neurol Neurosurg Psychiatry 1987; 50: 544–52.
58. Demirci M, Grill S, McShane L, et al. A mismatch between kinaesthetic and visual perception in Parkinson's disease. Ann Neurol 1997; 41: 781–8.
59. Fellows SJ, Noth J, Schwarz M. Precision grip and Parkinson's disease. Brain 1998; 121: 1771–84.
60. Rubinstein TC, Giladi N, Hausdorff JM. The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease. Mov Disord 2002; 17: 1148–60.
61. Marchese R, Diverio M, Zucchi F, et al. The role of sensory cues in the rehabilitation of parkinsonian patients: a comparison of two physical therapy protocols. Mov Disord 2000; 15: 879–83.
62. Morris ME, Iansek R, Matyas TA, et al. Stride length regulation in Parkinson's disease. Normalisation strategies and underlying mechanisms. Brain 1996; 119: 551–68.
63. Ito N, Hayshi A, Lin W, et al. Music therapy in Parkinson's disease: improvement of parkinsonian gait and depression with rhythmic auditory stimulation. In Nakada N, ed. Integrated Human Brain Science. New York, NY: Elsevier Science, 2000; 435–43.
64. Azulay J, Mesure S, Amblard B, et al. Visual control of locomotion in Parkinson's disease. Brain 1999; 117: 1169–81.
65. Müller V, Mohr B, Rosin R, et al. Short-term effects of behavioral treatment on movement initiation and postural control in Parkinson's disease: a controlled clinical study. Mov Disord 1997; 12: 306–14.
66. Dam M, Tonin P, Casson S. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's disease patients. Adv Neurol 1996; 69: 551–5.
67. Martin JP. The Basal Ganglia and Posture. London: Pitman, 1967.
68. Dietz, MA, Goetz CG, Stebbins GT. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord 1990; 5: 243–7.
69. Stern GM, Lander CM, Lees AJ. Akinetic freezing and trick movements in Parkinson's disease. J Neural Transm Suppl 1980; 16: 137–41.
70. Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Mov Disord 1996; 11: 193–200.
71. McIntosh GC, Brown SH, Rice RR, et al. Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 22–6.
72. Morris ME, Iansek R, Matyas TA, et al. Ability to modulate walking cadence remains intact in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 1532–4.
73. Behrman A, Teitelbaum P, Cauraugh J. Verbal instructional sets to normalize the temporal and spatial gait variables in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 65: 580–2.
74. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007; 78: 134–40.
75. Jöbges M, Heuschkel G, Pretzel C, et al. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75: 1682–7.
76. Hirsch MA, Toole T, Maitland CG, et al. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil 2003; 84(8): 1109–17.
77. Mirelman A, Maidan I, Herman T, et al. Virtual reality for gait training: can it induce motor learning to enhance complex walking and reduce fall risk in patients with Parkinson's disease? J Gerontol A Med Sci 2011; 66: 234–40.
78. Sato Y, Iwamoto J, Honda Y. Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 22–6.
79. Shahed J, Jankovic J. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord 2001; 16: 114–18.
80. Ramig LO, Countryman S, O'Brien C, et al. Intensive speech treatment for patients with Parkinson's disease: short- and long-term comparison of two techniques. Neurology 1996; 47: 1496–504.
81. Ramig LO, Sapir S, Fox C, et al. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord 2001; 16: 79–83.
82. Robertson SJ, Thomson F. Speech therapy in Parkinson's disease: a study of the efficacy and long term effects of intensive treatment. Br J Disord Commun 1984; 19: 213–24.
83. Johnson JA, Prang TR. Speech therapy and Parkinson's disease: a review and further data. Br J Disord Commun 1990; 25: 183–94.
84. Bine JE, Frank EM, McDade HL. Dysphagia and dementia in subjects with Parkinson's disease. Dysphagia 1995; 10: 160–4.
85. Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson's disease. Dysphagia 1996; 11: 14–22.
86. Bushmann M, Dobmeyer SM, Leeker L, et al. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989; 39: 1309–14.
87. Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson's disease. Scand J Rehabil Med 2000; 32: 11–15.
88. El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing treatment and voice effects of Lee Silverman Voice Treatment (LSVT®): a pilot study. J Neurol Neurosurg Psychiatry 2002; 72: 31–6.
89. Troche MS, Okun MS, Rosenbek JC, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST. Neurology 2010; 75: 1912–19.
90. Clarke CE, Gullaksen E, Macdonald S, et al. Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson's disease. Acta Neurol Scand 1998; 97: 27–35.
91. Ellgring H, Seiler S, Perleth B, et al. Psychosocial aspects of Parkinson's disease. Neurology 1993; 43: S41–4.
92. Montgomery EB, Lieberman A, Singh G, et al. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. Am J Med 1994; 97: 429–35.
93. Oppenheim H. Über eine eigenartige Krampfkrankheit des kindlichen und jugendlichen Alters (dystonica lordotica progressiva, dystonia musculorum deformans). Neurologisches Zentralblatt 1911; 30: 1090–107.
94. Fahn S. The varied clinical expression of dystonia. Neurol Clin 1984; 2: 541–54.
95. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994; 117: 859–76.
96. Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov. Disord 1988; 2: 188–194.
97. Ozelius L, Kramer PL, Moskowitz CB, et al. Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron 1989; 2: 1427–34.
98. Bressman SB, de Leon D, Brin MF, et al. Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol 1989; 26: 612–20.
99. Flechter NA. The genetics of idiopathic torsion dystonia. J Med Genet 1990; 27: 409–12.
100. Kramer PL, Heiman GA, Gasser T, et al. The DYT1 gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. Am J Genet 1994; 55: 468–75.
101. Pauls DL, Korczyn AD. Complex segregation analysis of dystonia pedigrees suggests autosomal dominant inheritance. Neurology 1990; 40: 1107–10.
102. Risch NJ, Bressmann SB, de Leon D, et al. Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet 1990; 46: 533–8.
103. Zilber N, Korczyn AD, Kahana E, et al. Inheritance of idiopathic torsion dystonia among Jews. J Med Genet 1984; 12: 13–20.
104. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17: 40–8.
105. Neuwald AF, Aravind L, Spouge JL, et al. AAA+: a class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. Genome Res 1999; 9: 27–43.
106. Torres GE, Sweeney AL, Beaulieu JM, et al. Effect of torsionA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsionA mutant. Proc Natl Acad Sci U S A 2004; 101: 15650–5.
107. O' Farrell CA, Martin KL, Hutton M, et al. Mutant torsinA interacts with tyrosine hydroxylase in cultured cells. Neuroscience 2009; 164: 1127–37.
108. McNaught KS, Kapustin A, Jackson T, et al. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol 2004; 56: 540–7.
109. Ozelius LJ, Bressman SB. Genetic and clinical features of primary torsion dystonia. Neurobiol Dis 2011; 42: 127–35.
110. Berardelli A, Rothwell JC, Hallet M, et al. The pathophysiology of primary dystonia. Brain 1998; 121: 1195–212.
111. Deuschl G, Toro C, Matsumoto J, et al. Movement-related cortical potentials in writer's cramp. Ann Neurol 1995; 38: 509–14.
112. Ikoma K, Samii A, Mercuri B, et al. Abnormal cortical motor excitability in dystonia. Neurology 1996; 46: 1371–6.
113. Kaji R, Ikeda A, Ikeda T, et al. Physiological study of cervical dystonia. Task specific abnormality in contingent negative variation. Brain 1995; 118: 511–22.
114. Rothwell JC, Obeso JA, Day BL, et al. Pathophysiology of dystonias. Motor control mechanisms in health and disease. In Desmedt JE, ed. Motor Control Mechanisms in Health and Disease. New York, NY: Raven Press, 1983; 851–72.
115. Tolosa E, Montserrat L, Bayes A. Blink reflex studies in focal dystonias: enhanced excitability of brainstem interneurons in cranial dystonia and spasmodic torticollis. Mov Disord 1988; 3: 61–9.
116. Sohn YH, Hallett M. Disturbed surround inhibition in focal hand dystonia. Ann Neurol 2004; 56: 595–9.
117. Edwards MJ, Huang YZ, Wood NW, et al. Different patterns of electrophysiological deficits in manifesting and non-manifesting carriers of the DYT1 gene mutation. Brain 2003; 126: 2074–80.
118. Espay AJ, Morgante F, Purzner J, et al. Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol 2006; 59: 825–34.
119. Wissel J, Müller J, Poewe W. EMG for identification of dystonic, tremulous and spastic muscles and techniques for guidance of injections. In Moore P, Naumann M, eds. Handbook of Botulinum Toxin Treatment. Malden, MA: Blackwell Science, 2003; 76–98.
120. Yanagisawa N, Goto A. Dystonia musculorum deformans: analysis with electromyography. J Neurol Sci 1971; 13: 39–65.
121. Cohen LG, Hallett M. Hand cramps: clinical features and electromyographic patterns in a focal dystonia. Neurology 1988; 38: 1005–12.
122. Zhuang P, Li Y, Hallett M. Neuronal activity in the basal ganglia and thalamus in patients with dystonia. Clin Neurophysiol 2004; 115: 2542–57.
123. Byl NN, Merzenich MM, Cheung S, et al. A primate model for studying focal dystonia and repetitive strain injury: effects on the primary somatosensory cortex. Phys Ther 1997; 77: 269–84.
124. Bara-Jimenez W, Catalan MJ, Hallett M, et al. Abnormal somatosensory homunculus in dystonia of the hand. Ann Neurol 1998; 44: 828–31.
125. Edwards MJ, Huang YZ, Mir P, et al. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. Mov Disord 2006; 21: 2181–6.
126. Wissel J, Müller J, Ebersbach G, et al. Trick maneuvers in cervical dystonia: investigation of movement- and touch-related changes in polymyographic activity. Mov Disord 1999; 14: 994–9.
127. Molloy FM, Carr TD, Zeuner KE, et al. Abnormalities of spatial discrimination in focal and generalized dystonia. Brain 2003; 126: 2175–82.
128. Fiorio M, Gambarin M, Valente EM, et al. Defective temporal processing of sensory stimuli in DYT1 mutation carriers: a new endophenotype of dystonia? Brain 2007; 130: 134–42.
129. Scontrini A, Conte A, Defazio G, et al. Somatosensory temporal discrimination in patients with primary focal dystonia. J Neurol Neurosurg Psychiatry 2009; 80: 1315–19.
130. Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998; 44: 303–12.
131. Argyelan M, Carbon M, Niethammer M, et al. Cerebellothalamo-cortical connectivity regulates penetrance in dystonia. J Neurosci 2009; 29: 9740–7.
132. Bonilha L, de Vries PM, Vincent DJ, et al. Structural white matter abnormalities in patients with idiopathic dystonia. Mov Disord 2007; 22: 1110–16.
133. Bonilha L, der Vries PM, Hird MW, et al. Disrupted thalamic prefrontal pathways in patients with idopathic dystonia. Parkinsonism Relat Disord 2009; 15: 64–7.
134. Carbon M, Kingsley PB, Su S, et al. Microstructural white matter changes in carriers of the SYT 1 gene mutation. Ann Neurol 2004; 56: 283–6.
135. Fabbrini G, Panatona P, Totaro P, et al. Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm. Eur J Neurol 2008; 15: 185–9.
136. Luft AR, Manto MU, Ben Taib NO. Modulation of motor cortex excitability by sustained peripheral stimulation: the interaction between the motor cortex and the cerebellum. Cerebellum 2005; 4: 90–6.
137. Manto MU. On the cerebello-cerebral interactions. Cerebellum 2006; 5: 286–8.
138. Molinari M, Filipponi V, Leggio MG. Neuronal plasticity of interrelated cerebellar and cortical networks. Neuroscience 2002; 111: 863–70.
139. Schrag A, Trimble M, Quinn N, et al. The syndrome of fixed dystonia: an evaluation of 103 patients. Brain 2004; 127: 2360–72.
140. Segawa M, Nomura Y, Kase M. Diurnally fluctuating hereditary progressive dystonia. In Vinken PJ, Bruyn GW, Klawans HL, eds. Extrapyramidal Disorders. Vol 5. Amsterdam: Elsevier, 1986; 529–40.
141. Hallett M, Benecke R, Blitzer A, et al. Treatment of focal dystonias with botulinum neurotoxin. Toxicon 2009; 54: 628–33.
142. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75: 951–7.
143. Simpson DM, Blitzer A, Brashear A, et al. Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1699–706.
144. Comella LC, Buchmann AS, Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992; 42: 878–82.
145. Fietzek UM, Schroeder AS, Wissel J, et al. Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin. Mov Disord 2010; 25: 2225–8.
146. Molloy FM, Shill HA, Kaelin-Lang A, et al. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 2002; 58: 805–7.
147. Schroeder AS, Berweck S, Lee SH, et al. Botulinum toxin treatment of children with cerebral palsy–a short review of different injection techniques. Neurotox Res 2006; 9: 189–96.
148. Balash Y, Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004; 11: 361–70.
149. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev 2005; 1:CD004312.
150. Gimenez-Roldan S, Mateo D, Martin M. Life-threatening cranial dystonia following trihexyphenidyl withdrawal. Mov Disord 2004; 18: 349–53.
151. Marsden CD, Marion MH, Quinn NP. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984; 47: 1166–73.
152. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986; 36: 160–4.
153. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46: 1066–72.
154. Greene PE, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 1988; 3: 46–60.
155. Albright AL, Barry MJ, Shafton DH, et al. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001; 43: 652–7.
156. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355: 1978–90.
157. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352: 459–67.
158. Cif L, El Fertit H, Vayssiere N, et al. Treatment of dystonic syndromes by chronic electrical stimulation of the internal globus pallidus. J Neurosurg Sci 2003; 47: 52–5.
159. Yianni J, Bain P, Giladi N, et al. Globus pallidus internus deep brain stimulation for dystonic conditions–a prospective audit. Mov Disord 2003; 18: 436–42.
160. Cif L, Vasques X, Gonzalez V, et al. Long-term follow-up of DYT 1 dystonia patients treated by deep brain stimulation: an open-label study. Mov Disord 2010; 25: 289–99.
161. Isaias IU, Altermann RL, Tagliati M. Deep brain stimulation for primary generalized dystonias: long-term outcomes. Arch Neurol 2009; 66: 465–70.
162. Andrews C, Aviles-Olmos I, Hariz M, et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010; 81: 1383–89.
163. Borggraefe I, Mehrkens JH, Telegravciska M, et al. Bilateral pallidal stimulation in children and adolescents with primary generalized dystonia-report of six patients and literature-based analysis of predictive outcomes variables. Brain Dev 2010; 32: 223–8.
164. Isaias IU, Alterman RL, Tagliati M. Outcome predictors of pallidal stimulation in patients with primary dystonia: the role of disease duration. Brain 2008; 131: 1895–902.
165. Speelman JD, Contarino MF, Schuurman PR, et al. Deep brain stimulation for dystonia: patient selection and outcomes. Eur J Neurol 2010; 17: 102–6.
166. Vasques X, Cif L, Gonzalez V, et al. Factor predicting improvement in primary generalized dystonia treated by pallidal deep brain stimulation. Mov Disord 2009; 24: 846–53.
167. Capelle HH, Blahak C, Schrader C, et al. Chronic deep brain stimulation in patients with tardive dystonia without a history of major psychosis. Mov Disord 2010; 25: 1477–81.
168. Castelnau P, Cif L, Valente EM, et al. Pallidal stimulation improves pantothenate kinase associated neurodegeneration. Ann Neurol 2005; 57: 738–41.
169. Chang EF, Schrock LE, Starr PA, et al. Long-term benefit sustained after bilateral pallidal deep brain stimulation in patients with refractory tardive dystonia. Stereotact Funct Neurosurg 2010; 88: 304–10.
170. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009; 73: 53–8.
171. Krause M, Fogel W, Tronnier V, et al. Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration. Mov Disord 2006; 21: 2255–7
172. Mikati MA, Yehya A, Darwish H, et al. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol 2009; 13: 61–4.
173. Oyama G, Fernandez HH, Foote KD, et al. Differential response of dystonia and parkinsonism following globus pallidus internus deep brain stimulation in X-linked dystonia-parkinsonism (Lubag). Stereotact Funct Neurosurg 2010; 88: 329–3.
174. Vidailhet M, Yelnik J, Lagrange C, et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8: 709–17.
175. Wadia PM, Lim SY, Lozano AM, et al. Bilateral pallidal stimulation for X-linked dystonia parkinsonism. Arch Neurol 2010; 67: 1012–5.
176. Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg 2003; 98: 1247–54.
177. Delnooz CCS, Horstink MWIM, Tijssen MA, et al. Paramedical treatment in primary dystonia: a systematic review. Mov Disord 2009; 15: 2187–98.
178. Duddy J. Lack of influence of EMG feedback in relaxation training for spasmodic torticollis. Clin Rehabil 1995; 9: 297–303.
179. Jahanshahi M, Satory G, Marsden CD. EMG biofeedback treatment of torticollis: a controlled outcome study. Biofeedback Self Regul 1991; 16: 413–48.
180. Tassorelli C, Mancini F, Balloni L, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 2006; 21: 2240–43.
181. Berger H, van der Werf S, Horstink C, et al. Writer's cramp: restoration of striatal D2-binding after successful biofeedback-based sensorimotor training. Parkinsonism Relat Disord 2007; 13: 170–3.
182. Pohl C, Happe J, Klockgether T. Cooling improves the writing performance of patients with writer's cramp. Mov Disord 2002; 17: 1341–44.
183. Schenk T, Bauer B, Steidle B, et al. Does training improve writer's cramp? An evaluation of a behavioural treatment approach using kinematic analysis. J Hand Ther 2004; 17: 349–63.
184. Zeuner KE, Shill HA, Sohn YH, et al. Motor training as treatment in focal hand dystonia. Mov Disord 2005; 20: 335–41.
185. Muller J, Wissel J, Schuss D, et al. Visual biofeedback treatment of torticollis with a portable and easy-to-use personal training device. Mov Disord 2008; 1: S171.
186. Bleton JP. Spasmodic torticollis. Handbook of Rehabilitative Physiotherapy. Paris: Frison-Roche, 1994.
187. Samania N, Corato E, Tinazzi M, et al. The effect of two different rehabilitation treatments in cervical dystonia: preliminary results in four patients. Funct Neurol 2003; 18: 219–25.
188. Leis AA, Dimitrijevic MR, Delapasse JS, et al. Modification of cervical dystonia by selective sensory stimulation. J Neurol Sci 1992; 110: 79–89.
189. Schuele S, Lederman RJ. Long-term outcome of focal dystonia in string instrumentalists. Mov Disord 2004; 19: 43–8.
190. Byl NN, Nagajaran S, McKenzie AL. Effect of sensory discrimination training on structure and function in patients with focal hand dystonia: a case series. Arch Phys Med Rehabil 2003; 84: 1505–14.
191. Zeuner KE, Hallett M. Sensory training as treatment for focal hand dystonia: a 1-year follow-up. Mov Disord 2003; 18: 1044–7.
192. Tinazzi M, Zarattini S, Valeriani M, et al. Long-lasting modulation of human motor cortex following prolonged transcutaneous electrical nerve stimulation (TENS) of forearm muscles: evidence of reciprocal inhibition and facilitation. Exp Brain Res 2004; 161: 457–64.
193. Lefaucheur JP, Fenelon G, Menard-Lefaucheur I, et al. Low-frequency repetitive TMS of premotor cortex can reduce painful axial spasms in generalized secondary dystonia: a pilot study of three patients. Neurophysiol Clin 2004; 34: 141–5.
194. Murase N, Rothwell JC, Kaji R, et al. Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex modulates writer's cramp. Brain 2005; 128: 104–15.
195. Byl NN, Nagarajan SS, Merzenich MM, et al. Correlation of clinical neuromusculoskeletal and central somatosensory performance: variability in controls and patients with severe and mild focal hand dystonia. Neural Plast 2002; 9: 177–203.
196. Jankovic J. Tics and Tourette syndrome. In Jankovic JJ, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2002; 311–30.
197. Zinzi P, Salmaso D, De Grandis R, et al. Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study. Clin Rehabil 2007; 21: 603–13.

References

1. WHO. International Classification of Functioning, Disability and Health (ICF), 2001.
2. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011; 377: 1693–702.
3. Wang D, Bakhai A. Clinical Trials. A Practical Guide to Design, Analysis, and Reporting. London: Remedica, 2006.
4. Katz MH. Multivariate Analysis. A Practical Guide for Clinicians. Cambridge: Cambridge University Press, 1999.
5. Altman D. Systematic reviews of evaluations of prognostic variables. BMJ 2001; 323: 224–8.
6. Kleinbaum DG, Kupper LL, Muller KE, et al. Applied Regression Analysis and other Multivariable Methods. 3rd edn. Pacific Grove: Duxbury Press, 1998.
7. Miller E, Murray L, Richards L, et al. Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient: a scientific statement from the American Heart Association. Stroke 2010; 41: 2402–48.
8. Hachinski V, Donnan G, Gorelick P, et al. Stroke: working toward a prioritized world agenda. Stroke 2010; 41: 1084–99.
9. Cramer SC. Stratifying patients with stroke in trials that target brain repair. Stroke 2010; 41: S114–16.
10. Moons K, Royston P, Vergouwe Y, et al. Prognosis and prognostic research: what, why, and how? BMJ 2010; 338: 1317–20.
11. Kwakkel G, van Peppen R, Wagenaar RC, et al. Effects of augmented exercise therapy time after stroke: a meta-analysis. Stroke 2004; 35: 2529–39.
12. Van Peppen RP, Kwakkel G, Wood-Dauphinee S, et al. The impact of physical therapy on functional outcomes after stroke: what's the evidence? Clin Rehabil 2004; 18: 833–62.
13. Young F, Lees K, Weir C. Improving trial power through use of prognosis-adjusted end points. Stroke 2005; 3: 597–601.
14. Kwakkel G, Veerbeek J, van Wegen E, et al. Predictive value of the NIHSS for ADL outcome after ischemic hemispheric stroke: does timing of early assessment matter? J Neurol Sci 2010; 294: 57–61.
15. Nijland RH, van Wegen EE, Harmeling-van der Wel BC, et al. Presence of finger extension and shoulder abduction within 72 hours after stroke predicts functional recovery. Stroke 2010; 41: 745–50.
16. Prabhakaran S, Zarahn E, Riley C, et al. Inter-individual variability in the capacity for motor recovery after ischemic stroke. Neurorehabil Neural Repair 2008; 22: 64–71.
17. Jørgenson H, Nakayama H, Raaschou H, et al. Recovery of walking function in stroke patients: the Copenhagen stroke study. Arch Phys Med Rehabil 1995; 76: 27–32.
18. Kollen B, Kwakkel G, Lindeman E. Longitudinal robustness of variables predicting independent gait following severe middle cerebral artery stroke: a prospective cohort study. Clin Rehabil 2006; 20: 262–8.
19. Kwakkel G, Kollen BJ, van der Grond J, et al. Probability of regaining dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in acute stroke. Stroke 2003; 34: 2181–6.
20. Nakayama H, Jørgensen HS, Raaschou HO, et al. Recovery of upper extremity function in stroke patients: the Copenhagen stroke study. Arch Phys Med Rehabil 1994; 75: 394–8.
21. Wade D, Hewer R. Functional abilities after stroke measurement, natural history and prognosis. J Neurol Neurosurg Psychiatry 1987; 50: 177–82.
22. Kwakkel G, Wagenaar R, Kollen B, et al. Predicting disability in stroke–a critical review of the literature. Age Ageing 1996; 25: 479–89.
23. Counsell C, Dennis M. Systematic review of prognostic models in patients with acute stroke. Cerebrovasc Dis 2001; 12: 159–70.
24. Veerbeek JM, Kwakkel G, van Wegen EE, et al. Early prediction of outcome of activities of daily living after stroke: a systematic review. Stroke 2011; 42: 1482–8.
25. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001; 357: 1191–4.
26. Hayden J, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2004; 144: 427–37.
27. Moons KG, Altman DG, Vergouwe Y, et al. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 2009; 4: 606.
28. Von Elm E, Altman D, Egger M, et al. The strengthening of reporting of observational studies in epidemiology (STROBE): guidelines for reporting observational studies. Lancet 2008; 370: 1453–7.
29. Meijer R, van Limbeek J, Kriek B, et al.. Prognostic social factors in the subacute phase after a stroke for the discharge destination from the hospital stroke-unit. A systematic review of the literature. Disabil Rehabil 2004; 26: 191–7.
30. Rothman KJ, Greenland S. Modern Epidemiology. 2nd edn. Philadelphia, PA: Lippincott Williams and Wilkins, 1998.
31. Kwakkel G, Kollen B, Twisk J. Impact of time on improvement of outcome after stroke. Stroke 2006; 37: 2348–53.
32. Van de Port IG, Kwakkel G, van Wijk I, et al. Susceptibility to deterioration of mobility long-term after stroke: a prospective cohort study. Stroke 2006; 37: 167–71.
33. Kwakkel G, Kollen B, Lindeman E. Understanding the pattern of functional recovery after stroke: facts and theories. Restor Neurol Neurosci 2004; 22: 281–99.
34. Koyama T, Matsumoto K, Okuno T, et al. A new method for predicting functional recovery of stroke patients with hemiplegia: logarithmic modelling. Clin Rehabil 2005; 19: 779–89.
35. Zarahn E, Alon L, Ryan SL, et al. Prediction of motor recovery using initial impairment and fMRI 48 h poststroke. Cereb Cortex 2011; 21: 2712–21.
36. Andrews K, Brocklehurst JC, Richards B, et al. The rate of recovery from stroke–and its measurement. Int Rehabil Med 1981; 3: 155–61.
37. Duncan PW, Goldstein LB, Matchar D, et al. Measurement of motor recovery after stroke. Outcome assessment and sample size requirements. Stroke 1992; 23: 1084–9.
38. Heller A, Wade DT, Wood VA, et al. Arm function after stroke: measurement and recovery over the first three months. J Neurol Neurosurg Psychiatry 1987; 50: 714–19.
39. Skilbeck C, Wade D, Hewer R, et al. Recovery after stroke. J Neurol Neurosurg Psychiatry 1983; 46: 5–8.
40. Duncan PW, Goldstein LB, Horner RD, et al. Similar motor recovery of upper and lower extremities after stroke. Stroke 1994; 25: 1181–8.
41. Gresham GE. Stroke outcome research. Stroke 1986; 17: 358–62.
42. Newman M. The process of recovery after hemiplegia. Stroke 1972; 3: 702–10.
43. van Hartingsveld F, Lucas C, Kwakkel G, et al. Improved interpretation of stroke trial results using empirical Barthel item weights. Stroke 2006; 37: 162–6.
44. Granger CV, Linn RT. Biologic patterns of disability. J Outcome Meas 2000; 4: 595–615.
45. Tennant A, Geddes JM, Fear J, et al. Outcome following stroke. Disabil Rehabil 1997; 19: 278–84.
46. Dallmeijer AJ, Dekker J, Roorda LD, et al. Differential item functioning of the Functional Independence Measure in higher performing neurological patients. J Rehabil Med 2005; 37: 346–52.
47. Nilsson AL, Sunnerhagen KS, Grimby G. Scoring alternatives for FIM in neurological disorders applying Rasch analysis. Acta Neurol Scand 2005; 111: 264–73.
48. Duncan PW, Bode RK, Min Lai S, et al. Rasch analysis of a new stroke-specific outcome scale: the Stroke Impact Scale. Arch Phys Med Rehabil 2003; 84: 950–63.
49. Heinemann AW, Harvey RL, McGuire JR, et al. Measurement properties of the NIH stroke scale during acute rehabilitation. Stroke 1997; 28: 1174–80.
50. Penta M, Tesio L, Arnould C, et al. The ABILHAND questionnaire as a measure of manual ability in chronic stroke patients: Rasch-based validation and relationship to upper limb impairment. Stroke 2001; 32: 1627–34.
51. Koh CL, Hsueh IP, Wang WC, et al. Validation of the action research arm test using item response theory in patients after stroke. J Rehabil Med 2006; 38: 375–80.
52. Daly JJ, Ruff RL. Construction of efficacious gait and upper limb functional interventions based on brain plasticity evidence and model-based measures for stroke patients. Sci Wld J 2007; 20: 2031–45.
53. Smith MT, Baer GD. Achievement of simple mobility milestones after stroke. Arch Phys Med Rehabil 1999; 80: 442–7.
54. Wade DT, de Jong BA. Recent advances in rehabilitation. BMJ 2000; 320: 1385–8.
55. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci 2009; 10: 861–72.
56. Dobkin BH. Rehabilitation after stroke. N Engl J Med 2005; 352: 1677–84.
57. Duncan P, Jørgensen H, Wade M. Outcome measures in acute stroke trials. A systematic review and some recommendations to improve practice. Stroke 2000; 31: 1429–38.
58. Kollen B, Van de Port I, Lindeman E, et al. Predicting improvement in gait after stroke: a longitudinal prospective study. Stroke 2005; 36: 2676–80.
59. Ween JE, Mernoff ST, Alexander MP. Recovery rates after stroke and their impact on outcome prediction. Neurorehabil Neural Repair 2000; 14: 229–35.
60. Goldstein H, Browne W, Rasbash J. Multilevel modeling of medical data. Stat Med 2002; 21: 3291–315.
61. Tilling K, Sterne J, Rudd A, et al. A new method for predicting recovery after stroke. Stroke 2001; 32: 2867–73.
62. Twisk JWR. Applied Multilevel Analysis. Cambridge: Cambridge University Press, 2006.
63. Ng YS, Stein J, Ning M, et al. Comparison of clinical characteristics and functional outcomes of ischemic stroke in different vascular territories. Stroke 2007; 38: 2309–14.
64. Löfgren B, Gustafson Y, Nyberg L. Psychological well-being 3 years after severe stroke. Stroke 1999; 30: 567–72.
65. Paolucci S, Grasso MG, Antonucci G, et al. Mobility status after inpatient stroke rehabilitation: 1-year follow-up and prognostic factors. Arch Phys Med Rehabil 2001; 82: 2–8.
66. Pohjasvaara T, Leppävuori A, Siira I, et al. Frequency and clinical determinants of poststroke depression. Stroke 1998; 29: 2311–17.
67. Kwakkel G, Kollen B, Wagenaar R. Long term effects of intensity of arm and leg training in stroke patients: a randomized trial. J Neurol Neurosurg Psychiatry 2002; 72: 473–9.
68. Kwakkel G, Veerbeek JM, Harmeling-van der Wel BC, et al. Diagnostic accuracy of the Barthel Index for measuring activities of daily living outcome after ischemic hemispheric stroke: does early poststroke timing of assessment matter? Stroke 2011; 42: 342–6.
69. Schiemanck SK, Kwakkel G, Post MW, et al. Predicting long-term independency in activities of daily living after middle cerebral artery stroke: does information from MRI have added predictive value compared with clinical information? Stroke 2006; 37: 1050–4.
70. Schiemanck SK, Kwakkel G, Post MW, et al. Predictive value of ischemic lesion volume assessed with magnetic resonance imaging for neurological deficits and functional outcome poststroke: a critical review of the literature. Neurorehabil Neural Repair 2006; 20: 492–502.
71. Adams HJ, del Zoppo G, Alberts M, et al. Guidelines for the early management of adults with ischemic stroke. Circulation 2007; 115: 478–534.
72. Kasner S. Clinical interpretation and use of stroke scales. Lancet Neurol 2006; 5: 603–12.
73. Jongbloed L. Prediction of function after stroke: a critical review. Stroke 1986; 17: 765–76.
74. Lord SE, Rochester L. Measurement of community ambulation after stroke: current status and future developments. Stroke 2005; 36: 1457–61.
75. Barer DH. Continence after stroke: useful predictor or goal of therapy? Age Aging 1989; 183: 183–91.
76. Sanchez-Blanco I, Ochoa-Sangrador C, Lopez-Munain I, et al. Predictive model of functional independence in stroke patients admitted to a rehabilitation programme. Clin Rehabil 1999; 13: 464–75.
77. Patel A, Duncan P, Lai S, et al. The relation between impairments and functional outcomes poststroke. Arch Phys Med Rehabil 2000; 81: 1357–63.
78. Franchignoni F, Tesio L, Ricupero C, et al. Trunk control test as an early predictor of stroke rehabilitation outcome. Stroke 1997; 28: 1382–5.
79. Loewen S, Anderson B. Predictors of stroke outcome using objective measurement scales. Stroke 1990; 21: 78–81.
80. Verheyden G, Nieuwboer A, De Wit L, et al. Time course of trunk, arm, leg, and functional recovery after ischemic stroke. Neurorehabil Neural Repair 2008; 22: 173–9.
81. Buurke J, Nene A, Kwakkel G, et al. Recovery of gait after stroke: what changes? Neurorehabil Neural Repair 2008; 22: 676–83.
82. De Haart M, Geurts A, Huidekoper S, et al. Recovery of standing balance in postacute stroke patients: a rehabilitation cohort study. Arch Phys Med Rehabil 2004; 85: 886–95.
83. Den Otter AR, Geurts AC, Mulder T, et al. Gait recovery is not associated with changes in the temporal patterning of muscle activity during treadmill walking in patients with post-stroke hemiparesis. Clin Neurophysiol 2006; 117: 4–15.
84. van Asseldonk EHF, Buurke JH, Bloem BR, et al. Disentangling the contribution of the paretic and non-paretic leg to balance control in stroke patients. Exp Neurol 2006; 201: 441–51.
85. Kirker SG, Jenner JR, Simpson DS, et al. Changing patterns of postural hip muscle activity during recovery from stroke. Clin Rehabil 2000; 14: 618–26.
86. Roerdink M, De Haart M, Daffertshofer A, et al. Dynamical structure of center-of-pressure trajectories in patients recovering from stroke. Exp Brain Res 2006; 174: 256–69.
87. Kollen BJ, Lennon S, Lyons B, et al. The effectiveness of the Bobath concept in stroke rehabilitation: what is the evidence? Stroke 2009; 40: e89–97.
88. Sunderland A, Fletcher D, Bradley L, et al. Enhanced physical therapy for arm function after stroke: a one year follow up study. J Neurol Neurosurg Psychiatry 1994; 57: 856–8.
89. Wade DT, Langton-Hewer R, Wood VA, et al. The hemiplegic arm after stroke: measurement and recovery. J Neurol Neurosurg Psychiatry 1983; 46: 521–4.
90. Beebe JA, Lang CE. Relationships and responsiveness of six upper extremity function tests during the first six months of recovery after stroke. J Neurol Phys Ther 2009; 33: 96–103.
91. Katrak P, Bowring G, Conroy P, et al. Predicting upper limb recovery after stroke: the place of early shoulder and hand movement. Arch Phys Med Rehabil 1998; 79: 758–61.
92. Smania N, Gambarin M, Tinazzi M, et al. Are indexes of arm recovery related to daily life autonomy in patients with stroke? Eur J Phys Rehabil Med 2009; 45: 349–54.
93. Smania N, Paolucci S, Tinazzi M, et al. Active finger extension: a simple movement predicting recovery of arm function in patients with acute stroke. Stroke 2007; 38: 1088–90.
94. Matsui T, Hirano A. An Atlas of the Human Brain for Computerized Tomography. Tokyo: Igaku-Shoin, 1978.
95. Pineiro R, Pendlebury ST, Smith S, et al. Relating MRI changes to motor deficit after ischemic stroke by segmentation of functional motor pathways. Stroke 2000; 31: 672–9.
96. Stinear C. Prediction of recovery of motor function after stroke. Lancet Neurol 2010; 9: 1228–32.
97. Fries W, Danek A, Scheidtmann K, et al. Motor recovery following capsular stroke. Role of descending pathways from multiple motor areas. Brain 1993; 116: 369–82.
98. Morecraft RJ, Herrick JL, Stilwell-Morecraft KS, et al. Localization of arm representation in the corona radiata and internal capsule in the non-human primate. Brain 2002; 125: 176–98.
99. Newton JM, Ward NS, Parker GJ, et al. Non-invasive mapping of corticofugal fibres from multiple motor areas–relevance to stroke recovery. Brain 2006; 129: 1844–58.
100. Stinear CM, Barber PA, Smale PR, et al. Functional potential in chronic stroke patients depends on corticospinal tract integrity. Brain 2007; 130: 170–80.
101. van Kuijk AA, Pasman JW, Hendricks HT, et al. Predicting hand motor recovery in severe stroke: the role of motor evoked potentials in relation to early clinical assessment. Neurorehabil Neural Repair 2009; 23: 45–51.
102. Pendlebury ST, Blamire AM, Lee MA, et al. Axonal injury in the internal capsule correlates with motor impairment after stroke. Stroke 1999; 30: 956–62.
103. Schiemanck SK, Kwakkel G, Post MW, et al. Impact of internal capsule lesions on outcome of motor hand function at one year post-stroke. J Rehabil Med 2008; 40: 96–101.
104. Fritz SL, Light KE, Patterson TS, et al. Active finger extension predicts outcomes after constraint-induced movement therapy for individuals with hemiparesis after stroke. Stroke 2005; 36: 1172–7.
105. Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA 2006; 296: 2095–104.

References

1.Stroke Rehabilitation. Canadian Stroke Strategy–Canadian Best Practice Recommendations For Stroke Care. 2010; 99–127.
2. Langhorne P, Duncan P. Does the organization of postacute stroke care really matter? Stroke 2001; 32: 268–75.
3. Teasell R, Foley N, Salter K, et al. Evidence-based Review of Stroke Rehabilitation. 13th edn. London: EBRSR, 2010.
4. Van Exel J, Koopmanschap MA, Van Wijngaarden JD, et al. Cost of stroke and stroke services: determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. Cost Eff Resour Alloc 2003; 1: 2.
5. Antithrombotic Trialist's Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71–86.
6. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
7. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998; 29: 1476–7.
8. Riopelle R, Howse D, Bolton C, et al. Regional access to acute ischemic stroke interventions. Stroke 2001; 32: 652–5.
9. Gilligan AK, Thrift AG, Sturm JW, et al. Tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit? Cerebrovasc Dis 2005; 20: 239–44.
10. Ween JE, Alexander MP, D'Esposito M, et al. Factors predictive of stroke outcome in a rehabilitation setting. Neurology 1996; 47: 388–92.
11. Alexander MP. Stroke rehabilitation outcome. A potential use of predictive variables to establish levels of care. Stroke 1994; 25: 128–34.
12. Lo RC. Recovery and rehabilitation after stroke. Can Fam Physician 1986; 32: 1851–3.
13. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia: the ischemic penumbra. Stroke 1981; 12: 723–5.
14. Nudo RJ, Plautz EJ, Frost SB. Role of adaptive plasticity in recovery of function after damage to motor cortex. Muscle Nerve 2001; 24: 1000–18.
15. Nudo RJ. Adaptive plasticity in motor cortex: implications for rehabilitation after brain injury. J Rehabil Med 2003; 41: 7–10.
16. Coq JD, Xerri C. Tactile impoverishment and sensorimotor restriction deteriorate the forepaw cutaneous map in the primary somatosensory cortex of adult rats. Exp Brain Res. 1999; 129: 518–31.
17. Cramer SC. Functional magnetic resonance imaging in stroke recovery. Phys Med Rehabil Clin N Am 2003; 14: S47–55.
18. Bergsneider M, Hovda D, Shalmon E, et al. Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. J Neurosurg 1997; 86: 241–51.
19. Maeda T, Lee SM, Hovda DA. Restoration of cerebral vasoreactivity by an L-type calcium channel blocker following fluid percussion brain injury. J Neurotrauma 2005; 22: 763–71.
20. Kelly DE, Martin NA, Kordestani R, et al. Cerebral blood flow as a predictor of outcome following traumatic brain injury. J Neurosurg 1997; 86: 633–41.
21. Ip E, Giza C, Griesbach GS, et al. Effects of enriched environment and fluid percussion injury on dendritic arborization within the cerebral cortex of the developing rat. J Neurotrauma 2002; 19: 573–85.
22. Humm JL, Kozlowski DA, Bland ST, et al. Use-dependent exaggeration of brain injury: is glutamate involved? Exp Neurol 1999; 157: 349–58.
23. Giza CC, Maria NSS, Hovda DA. N-methyl-D-aspartate receptor subunit changes after traumatic injury to the developing brain. J Neurotrauma 2006; 23: 950–61.
24. Griesbach GS, Hovda DA, Molteni R, et al. Voluntary exercise following traumatic brain injury: brain-derived neurotrophic factor upregulation and recovery of function. Neuroscience 2004; 125: 129–39.
25. Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitation experience declines with time after focal ischemic brain injury. J Neurosci 2004; 24: 1245–54.
26. Cifu D, Stewart D. Factors affecting functional outcome after stroke: a critical review of rehabilitation interventions. Arch Phys Med Rehabil 1999; 80: S35–9.
27. Paolucci S, Antonucci G, Grasso M, et al. Early versus delayed inpatient stroke rehabilitation: a matched comparison conducted in Italy. Arch Phys Med Rehabil 2000; 81: 695–700.
28. Salter K, Jutai J, Hartley M, et al. Impact of early vs delayed admission to rehabilitation on functional outcomes in persons with stroke. J Rehabil Med 2006; 38: 113–17.
29. Cumming TB, Thrift AG, Collier JM, et al. Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial. Stroke 2011; 42: 153–8.
30. Dromerick AW, Lang CE, Birkenmeier RL, et al. Very early constraint-induced movement during stroke rehabilitation (VECTORS): a single-center RCT. Neurology 2009; 73: 195–201.
31. De Wit L, Putman K, Dejaeger E, et al. Use of time by stroke patients: a comparison of four European rehabilitation centers. Stroke 2005; 36: 1977–83.
32. De Wit L, Putman K, Schuback B, et al. Motor and functional recovery after stroke: a comparison of 4 European rehabilitation centers. Stroke 2007; 38: 2101–7.
33. Conroy BE, DeJong G, Horn SD. Hospital-based stroke rehabilitation in the United States. Top Stroke Rehabil 2009; 16: 34–43.
34. Brunnstrom S. Motor testing procedures in hemiplegia; based on sequential recovery stages. Phys Ther 1966; 46: 357–75.
35. Lance J. The control of muscle tone, reflexes, and movement: Robert Wartenberg lecture. Neurology 1980; 30: 1303–13.
36. Gustafsson L, McKenna K. A programme of static positional stretches does not reduce hemiplegic shoulder pain or maintain shoulder range of motion–a randomized controlled trial. Clin Rehabil 2006; 20: 277–86.
37. Borisova Y, Bohannon R. Positioning to prevent or reduce shoulder range of motion impairments after stroke: a meta-analysis. Clin Rehabil 2009; 23: 681–6.
38. McCrory P, Turner-Stokes L, Baguley I, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009; 41: 536–44.
39. Childers M, Brashear A, Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004; 85: 1063–9.
40. Bakheit A, Pittock S, Moore A, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patient with stroke. Eur J Neurol 2001; 8: 559–65.
41. Gelber D, Good D, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001; 32: 1841–6.
42. Kamen L, Henney HR, Runyan J. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008; 24: 425–39.
43. Winstein C, Wolf S. Task oriented training to promote upper extremity recovery. In Stein RH, Macko CJ, Winstein RD, et al, eds. Recovery and Rehabilitation. New York, NY: Demos Medical Publishing, 2009.
44. Barreca S, Sigouin C, Lambert C, et al. Effects of extra training on the ability of stroke survivors to perform an independent sit-to-stand: a randomized controlled trial. J Geriatr Phys Ther 2004; 27: 59–64.
45. Dean C, Richards C, Malouin F. Task-related circuit training improves performance of locomotor tasks in chronic stroke: a randomized, controlled pilot trial. Arch Phys Med Rehabil 2000; 81: 409–17.
46. Cheng P-T, Wu S-H, Liaw M-Y, et al. Symmetrical body-weight distribution training in stroke patients and its effect on fall prevention. Arch Phys Med Rehabil 2001; 82: 1650–4.
47. Powell J, Pandyan A, Granat M, et al. Electrical stimulation of wrist extensors in poststroke hemiplegia. Stroke 1999; 30: 1384–9.
48. Pomeroy V, King L, Pollock A, et al. Electrostimulation for promoting recovery of movement or functional ability after stroke. Cochrane Database Syst Rev 2006; 2: CD003241.
49. Chan M-L, Tong R-Y, Chung K-K. Bilateral upper limb training with functional electric stimulation in patients with chronic stroke. Neurorehabil Neural Repair 2009; 23: 357–65.
50. Kottink A, Oostendorp L, Buurke J, et al. The orthotic effect of functional electrical stimulation on the improvement of walking in stroke patients with a dropped foot: a systematic review. Artif Organs 2004; 28: 577–86.
51. Taub E. Somatosensory deafferentation research with monkeys: implication for rehabilitation medicine. In Ince LP, ed. Behavioural Psychology in Rehabilitation Medicine. Baltimore, MD: Williams and Wilkins, 1980; 371–401.
52. Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. JAMA 2006; 296: 2095–104.
53. Lindgren I, Jonsson A, Norrving B, et al. Shoulder pain after stroke: a prospective population-based study. Stroke 2007; 38: 343–8.
54. Turner-Stokes L, Jackson D. Shoulder pain after stroke: a review of the evidence base to inform the development of an integrated care pathway. Clin Rehabil 2002; 16: 276–98.
55. Gamble G, Barberan E, Bowsher D, et al. Post stroke shoulder pain: more common than previously realized. Eur J Pain 2000; 4: 313–5.
56. Koog Y, Jin S, Yoon K, et al. Interventions for hemiplegic shoulder pain: systematic review of randomized control trials. Disabil Rehabil 2010; 32: 282–91.
57. Black-Schaffer R, Kirsteins A, Harvey R. Stroke rehabilitation. 2. Co-morbidities and complications. Am J Phys Med Rehabil 1999; 80: S8–16.
58. Lee I, Shin Y, Moon T, et al. Sonography of patients with hemiplegic shoulder pain after stroke: correlation with motor recovery stage. Am J Roentgenol 2009; 192: W40–4.
59. Huang Y, Liang P, Pong Y, et al. Physical findings and sonography of hemiplegic shoulder in patients after stroke during rehabilitation. J Rehabil Med 2010; 42: 21–6.
60. Pong Y, Wang L, Wang L, et al. Sonography of the shoulder in hemiplegic patients undergoing rehabilitation after a recent stroke. J Clin Ultrasound 2009; 37: 199–205.
61. Renzenbrick G, Ijzerman M. Percutaneous neuromuscular electrical stimulation (P-NMES) for treating shoulder pain in chronic hemiplegia. Effects on shoulder pain and quality of life. Clin Rehabil 2004; 18: 359–65.
62. Chae J, Yu D, Walker M, et al. Intramuscular electrical stimulation for hemiplegic shoulder pain: a 12-month follow-up of a multiple-center, randomized clinical trial. Am J Phys Med Rehabil 2005; 84: 832–42.
63. Vuagnat H, Chantraine A. Shoulder pain in hemiplegia revisited: contributions of functional electrical stimulation and other therapies. J Rehabil Med 2003; 35: 49–56.
64. Koyuncu E, Nakipoglu-Yuzer G, Dogan A, et al. The effectiveness of functional electrical stimulation for the treatment of shoulder subluxation and shoulder pain in hemiplegic patients: a randomized control trial. Disabil Rehabil 2010; 7: 560–6.
65. Snels I, Beckerman H, Twisk J, et al. Effect of triamcinolone acetonide injections on hemiplegic shoulder pain: a randomized clinical trial. Stroke 2000; 31: 2396–401.
66. Kong K, Neo J, Chua K. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin Rehabil 2007; 21: 28–35.
67. Lim J, Koh J, Paik N. Intramuscular botulinum toxin-A reduces hemiplegic shoulder pain: a randomized, double-blind, comparative study versus intraarticular triamcinolone acetonide. Stroke 2008; 39: 126–31.
68. Marco E, Duarte E, Vila J, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J Rehabil Med 2007; 39: 440–7.
69. Moseley A, Stark A, Cameron I, et al. Treadmill training and body weight support for walking after stroke. Cochrane Database Syst Rev 2003; 3: CD002840.
70. Lindsay P, Bayley M, McDonald A, et al. Toward a more effective approach to stroke: Canadian best practice recommendations for stroke care CMAJ 2010; 178: 1418–25.
71. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington: American Psychiatric Association, 1994.
72. Ferro J, Mariano G, Madureira S. Recovery from aphasia and neglect. Cardiovasc Dis 1999; 9: 6–22.
73. Robey R. A meta-analysis of clinical outcomes in the treatment of aphasia. J Speech Lang Hear Res 1998; 41: 172–87.
74. Bhogal SK, Teasell R, Speechley M. Intensity of aphasia therapy, impact on recovery. Stroke 2003; 34: 987–93.
75. Martino R, Pron G, Diamant N. Screening for oropharyngeal dysphagia in stroke: insufficient evidence for guidelines. Dysphagia 2000; 15: 19–30.
76. Jean A. Brain stem control of swallowing: neuronal network and cellular mechanisms. Physiol Rev 2001; 81: 929–69.
77. Horner J, Massey E, Riski J, et al. Aspiration following stroke: clinical correlates and outcome. Neurology 1988; 38: 1359–62.
78. Navarrete-Navarro P, Rivera-Fernadez R, Lopez-Mutuberria M, et al. Outcome prediction in terms of functional disability and mortality at 1 year among ICU-admitted severe stroke patients: a prospective epidemiological study in the south of the European Union. Intens Care Med 2003; 29: 1237–44.
79. Teasell R, Foley N, Bhogal S, et al. A rehabilitation program for patients with severe stroke. Can J Neurol Sci 2005; 32: 512–17.
80. Jorgensen H, Kammersgaard L, Houth J, et al. Who benefits from treatment and rehabilitation in a stroke unit? A community-based study. Stroke 2000; 31: 434–9.
81. Pereira S, Graham R, Teasell R. Discharge destination of severe stroke patients undergoing rehabilitation: development of a predictive model. Stroke 2010; 41: e500.
82. Teasell R, Mehta S, Pereira S, et al. Time to rethink long-term rehabilitation management of stroke patients. Top Stroke Rehabil 2012; 19: 457–62.
83. Mehta S, Pereira S, Janzen S, et al. Cardiovascular conditioning for comfortable gait speed and total distance walked during the chronic stage of stroke: a meta-analysis. Top Stroke Rehabil 2012; 19: 463–70.
84. Mehta S, Pereira S, Viana R, et al. Resistance training for gait speed and total distance walked during the chronic stage of stroke: a meta-analysis. Top Stroke Rehabil 2012; 19: 471–8.
85. McIntyre A, Lee T, Janzen S, et al. Systematic review of the effectiveness of pharmacological interventions in the treatment of spasticity of the hemiparetic lower extremity more than six months post stroke. Top Stroke Rehabil 2012; 19: 479–90.
86. Pereira S, Mehta S, McIntyre A, et al. Functional electrical stimulation for improving gait in persons with chronic stroke. Top Stroke Rehabil 2012; 19: 491–8.
87. McIntyre A, Viana R, Janzen S, et al. Systematic review and meta-analysis of constraint-induced movement therapy in the hemiparetic upper extremity more than six months post stroke. Top Stroke Rehabil 2012; 19: 499–513.
88. Viana R, Pereira S, Mehta S, et al. Evidence for therapeutic interventions for hemiplegic shoulder pain during the chronic stage of stroke: a review. Top Stroke Rehabil 2012; 19: 514–22.
89. Allen L, Mehta S, McClure A, et al. Therapeutic interventions for aphasia initiated more than six months post stroke: a review of the evidence. Top Stroke Rehabil 2012; 19: 523–35.
90. Mehta S, Pereira S, Janzen S, et al. Effectiveness of psychological interventions in chronic stage of stroke: a systematic review. Top Stroke Rehabil 2012; 19: 536–44.

References

1. Fehlings MG, Sekhon LH. Acute interventions in spinal cord injury: what do we know, what should we do? Clin Neurosurg 2001; 48: 226–42.
2. van den Berg ME, Castellote JM, Mahillo-Fernandez I, et al. Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology 2010; 34: 184–92.
3. DeVivo MJ, Black KJ, Stover SL. Causes of death during the first 12 years after spinal cord injury. Arch Phys Med Rehab 1993; 74: 248–54.
4. Guilcher SJ, Munce SE, Couris CM, et al. Health care utilization in non-traumatic and traumatic spinal cord injury: a population-based study. Spinal Cord 2010; 48: 45–50.
5. Gupta A, Taly AB, Srivastava A, et al. Non-traumatic spinal cord lesions: epidemiology, complications, neurological and functional outcome of rehabilitation. Spinal Cord 2009; 47: 307–11.
6. McCammon JR, Ethans K. Spinal cord injury in Manitoba: a provincial epidemiological study. J Spinal Cord Med 2011; 34: 6–10.
7. New PW, Simmonds F, Stevermuer T. A population-based study comparing traumatic spinal cord injury and non-traumatic spinal cord injury using a national rehabilitation database. Spinal Cord 2011; 49: 397–403.
8. Tan M, New P. Survival after rehabilitation for spinal cord injury due to tumor: a 12-year retrospective study. J Neurooncol 2011; 104: 233–8.
9. van den Berg ME, Castellote JM, de Pedro-Cuesta J, et al. Survival after spinal cord injury: a systematic review. J Neurotrauma 2010; 27: 1517–28.
10. Scivoletto G, Farchi S, Laurenza L, et al. Traumatic and non-traumatic spinal cord lesions: an Italian comparison of neurological and functional outcomes. Spinal Cord 2011; 49: 391–6.
11. Dijkers M. Quality of life after spinal cord injury: a meta analysis of the effects of disablement components. Spinal Cord 1997; 35: 829–40.
12. American Spinal Injury Association. International Standards for Neurological Classification of Spinal Cord Injury, 2000.
13. McKinley W, Santos K, Meade M, et al. Incidence and outcomes of spinal cord injury clinical syndromes. J Spinal Cord Med 2007; 30: 215–24.
14. Kumral E, Polat F, Gulluoglu H, et al. Spinal ischaemic stroke: clinical and radiological findings and short-term outcome. Eur J Neurol 2011; 18: 232–9.
15. Ozer MN, Gibson L. Neurological consultation for persons with spinal cord injury. In Redford JB, ed. Physical Medicine and Rehabilitation: State of the Art Reviews. Philadelphia, PA, 1987; 3401.
16. Schneider RC, Cherry G, Pantek H. The syndrome of acute central cervical spinal cord injury; with special reference to the mechanisms involved in hyperextension injuries of cervical spine. J Neurosurg 1954; 11: 546–77.
17. Song J, Mizuno J, Nakagawa H, et al. Surgery for acute subaxial traumatic central cord syndrome without fracture or dislocation. J Clin Neurosci 2005; 12: 438–43.
18. van Middendorp JJ, Pouw MH, Hayes KC, et al. Diagnostic criteria of traumatic central cord syndrome. Part 2: a questionnaire survey among spine specialists. Spinal Cord 2010;48: 657–63.
19. Kobayashi N, Asamoto S, Doi H, et al. Brown-Sequard syndrome produced by cervical disc herniation: report of two cases and review of the literature. Spine J 2003; 3: 530–3.
20. Taylor RG, Gleave JR. Incomplete spinal cord injuries with Brown-Sequard phenomena. J Bone Joint Surg (Br) 1957; 39B: 438–50.
21. Waters RL, Sie I, Adkins RH, et al. Motor recovery following spinal cord injury caused by stab wounds: a multicenter study. Paraplegia 1995; 33: 98–101.
22. Harrop JS, Naroji S, Maltenfort MG, et al. Neurologic improvement after thoracic, thoracolumbar, and lumbar spinal cord (conus medullaris) injuries. Spine (Phila Pa 1976) 2011; 36: 21–5.
23. Sinclair A, Davies N. Neurological picture. Conus medullaris lesion causing bilateral lower limb myokymia. J Neurol Neurosurg Psychiatry 2007; 78: 1136.
24. Demetriades AK, Naik S, Gunasekera L. Conus medullaris syndrome from a transdural disc herniation at the thoracolumbar junction. Acta Neurochir (Wien) 2010; 152: 1081–2.
25. Curt A, Dietz V. Electrophysiological recordings in patients with spinal cord injury: significance for predicting outcome. Spinal Cord 1999; 37: 157–65.
26. Ellaway PH, Anand P, Bergstrom EM, et al. Towards improved clinical and physiological assessments of recovery in spinal cord injury: a clinical initiative. Spinal Cord 2004; 42: 325–37.
27. Ellaway PH, Catley M, Davey NJ, et al. Review of physiological motor outcome measures in spinal cord injury using transcranial magnetic stimulation and spinal reflexes. J Rehabil Res Dev 2007; 44: 69–76.
28. Dietz V, Curt A. Neurological aspects of spinal-cord repair: promises and challenges. Lancet Neurol 2006; 5: 688–94.
29. Curt A, Van Hedel HJ, Klaus D, et al. Recovery from a spinal cord injury: significance of compensation, neural plasticity, and repair. J Neurotrauma 2008; 25: 677–85.
30. Chabot R, York DH, Watts C, et al. Somatosensory evoked potentials evaluated in normal subjects and spinal cord-injured patients. J Neurosurg 1985; 63: 544–51.
31. Nuwer MR. Spinal cord monitoring. Muscle Nerve 1999; 22: 1620–30.
32. Chen R, Cros D, Curra A, et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2008; 119: 504–32.
33. Hess CW, Mills KR, Murray NM, et al. Magnetic brain stimulation: central motor conduction studies in multiple sclerosis. Ann Neurol 1987; 22: 744–52.
34. Rothwell JC. Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. J Neurosci Methods 1997; 74: 113–22.
35. Curt A, Weinhardt C, Dietz V. Significance of sympathetic skin response in the assessment of autonomic failure in patients with spinal cord injury. J Auton Nerv Syst 1996; 61: 175–80.
36. Curt A, Nitsche B, Rodic B, et al. Assessment of autonomic dysreflexia in patients with spinal cord injury. J Neurol Neurosurg Psychiatry 1997; 62: 473–7.
37. Nitsche B, Perschak H, Curt A, et al. Loss of circadian blood pressure variability in complete tetraplegia. J Hum Hypertens 1996; 10: 311–17.
38. van Hedel HJ, Curt A. Fighting for each segment: estimating the clinical value of cervical and thoracic segments in SCI. J Neurotrauma 2006; 23: 1621–31.
39. Kramer JL, Moss AJ, Taylor P, et al. Assessment of posterior spinal cord function with electrical perception threshold in spinal cord injury. J Neurotrauma 2008; 25: 1019–26.
40. Zariffa J, Kramer JL, Fawcett JW, et al. Characterization of neurological recovery following traumatic sensorimotor complete thoracic spinal cord injury. Spinal Cord 2011; 49: 463–71.
41. Chen AC, Niddam DM, Arendt-Nielsen L. Contact heat evoked potentials as a valid means to study nociceptive pathways in human subjects. Neurosci Lett 2001; 316: 79–82.
42. Granovsky Y, Matre D, Sokolik A, et al. Thermoreceptive innervation of human glabrous and hairy skin: a contact heat evoked potential analysis. Pain 2005; 115: 238–47.
43. Wydenkeller S, Wirz R, Halder P. Spinothalamic tract conduction velocity estimated using contact heat evoked potentials: what needs to be considered. Clin Neurophysiol 2008; 119: 812–21.
44. Curt A, Dietz V. Nerve conduction study in cervical spinal cord injury: significance for hand function. Neurorehabil Neural Repair 1996; 7: 165–73.
45. Kelleher MO, Tan G, Sarjeant R, et al. Predictive value of intraoperative neurophysiological monitoring during cervical spine surgery: a prospective analysis of 1055 consecutive patients. J Neurosurg Spine 2008; 8: 215–21.
46. Curt A, Keck ME, Dietz V. Functional outcome following spinal cord injury: significance of motor-evoked potentials and ASIA scores. Arch Phys Med Rehabil 1998; 79: 81–6.
47. Diehl P, Kliesch U, Dietz V, et al. Impaired facilitation of motor evoked potentials in incomplete spinal cord injury. J Neurol 2006; 253: 51–7.
48. Petersen NT, Butler JE, Marchand-Pauvert V, et al. Suppression of EMG activity by transcranial magnetic stimulation in human subjects during walking. J Physiol 2001; 537: 651–6.
49. Iseli E, Cavigelli A, Dietz V, et al Prognosis and recovery in ischaemic and traumatic spinal cord injury: clinical and electrophysiological evaluation. J Neurol Neurosurg Psychiatry 1999; 67: 567–71.
50. Curt A, Dietz V. Traumatic cervical spinal cord injury: relation between somatosensory evoked potentials, neurological deficit, and hand function. Arch Phys Med Rehabil 1996; 77: 48–53.
51. Curt A, Dietz V. Ambulatory capacity in spinal cord injury: significance of somatosensory evoked potentials and ASIA protocol in predicting outcome. Arch Phys Med Rehab 1997; 78: 39–43.
52. Curt A, Rodic B, Schurch B, et al. Recovery of bladder function in patients with acute spinal cord injury: significance of ASIA scores and somatosensory evoked potentials. Spinal Cord 1997; 35: 368–73.
53. Cadotte DW, Fehlings MG. Spinal cord injury: a systematic review of current treatment options. Clin Orthop Relat Res 2011; 469: 732–41.
54. Furlan JC, Kailaya-Vasan A, Aarabi B, et al. A novel approach to quantitatively assess posttraumatic cervical spinal canal compromise and spinal cord compression: a multicenter responsiveness study. Spine (Phila Pa 1976) 2011; 36: 784–93.
55. Lenehan B, Fisher CG, Vaccaro A, et al. The urgency of surgical decompression in acute central cord injuries with spondylosis and without instability. Spine (Phila Pa 1976) 2010; 35: S180–6.
56. Jaksche H, Schaan M, Schulz J, et al. Posttraumatic syringomyelia–a serious complication in tetra- and paraplegic patients. Acta Neurochir Suppl 2005; 93: 165–7.
57. Lammertse D, Dungan D, Dreisbach J, et al. Neuroimaging in traumatic spinal cord injury: an evidence-based review for clinical practice and research. J Spinal Cord Med 2007; 30: 205–14.
58. Ditunno JF, Little JW, Tessler A, et al. Spinal shock revisited: a four-phase model. Spinal Cord 2004; 42: 383–95.
59. Adams MM, Hicks AL. Spasticity after spinal cord injury. Spinal Cord 2005; 43: 577–86.
60. Todd NV. Priapism in acute spinal cord injury. Spinal Cord 2011; 49: 1033–5.
61. Tibbs PA, Bivins BA, Young AB. The problem of acute abdominal disease during spinal shock. Am Surg 1979; 45: 366–8.
62. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540–2.
63. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206–7.
64. Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512–5.
65. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994; 17: 150–6.
66. Margot-Duclot A, Tournebise H, Ventura M, et al. What are the risk factors of occurrence and chronicity of neuropathic pain in spinal cord injury patients? Ann Phys Rehabil Med 2009; 52: 111–23.
67. Siddall PJ, Loeser JD. Pain following spinal cord injury. Spinal Cord 2001; 39: 63–73.
68. Siddall PJ, Taylor DA, Cousins MJ. Classification of pain following spinal cord injury. Spinal Cord 1997; 35: 69–75.
69. Robert R, Perrouin-Verbe B, Albert T, et al. Chronic neuropathic pain in spinal cord injured patients: what is the effectiveness of surgical treatments excluding central neurostimulations? Ann Phys Rehabil Med 2009; 52: 194–202.
70. Hoffman JM, Bombardier CH, Graves DE, et al. A longitudinal study of depression from 1 to 5 years after spinal cord injury. Arch Phys Med Rehabil 2011; 92: 411–18.
71. Kalpakjian CZ, Bombardier CH, Schomer K, et al. Measuring depression in persons with spinal cord injury: a systematic review. J Spinal Cord Med 2009; 32: 6–24.
72. Pollard C, Kennedy P. A longitudinal analysis of emotional impact, coping strategies and post-traumatic psychological growth following spinal cord injury: a 10-year review. Br J Health Psychol 2007; 12: 347–62.
73. Egner A, Phillips VL, Vora R, et al. Depression, fatigue, and health-related quality of life among people with advanced multiple sclerosis: results from an exploratory telerehabilitation study. NeuroRehabil 2003; 18: 125–33.
74. Elliott TR, Frank RG. Depression following spinal cord injury. Arch Phys Med Rehabil 1996; 77: 816–23.
75. Tamplin J, Brazzale DJ, Pretto JJ, et al. Assessment of breathing patterns and respiratory muscle recruitment during singing and speech in quadriplegia. Arch Phys Med Rehabil 2011; 92: 250–6.
76. Teasell RW, Hsieh JT, Aubut JA, et al. Venous thromboembolism after spinal cord injury. Arch Phys Med Rehabil 2009; 90: 232–45.
77. Consortium for Spinal Cord Medicine. Acute management of autonomic dysreflexia: adults with spinal cord injury presenting to health-care facilities. J Spinal Cord Med 1997; 20: 284–308.
78. Krassioukov A, Alexander MS, Karlsson AK, et al. International spinal cord injury cardiovascular function basic data set. Spinal Cord 2010; 48: 586–90.
79. Krassioukov A, Eng JJ, Warburton DE, et al. A systematic review of the management of orthostatic hypotension after spinal cord injury. Arch Phys Med Rehabil 2009; 90: 876–85.
80. Alan N, Ramer LM, Inskip JA, et al. Recurrent autonomic dysreflexia exacerbates vascular dysfunction after spinal cord injury. Spine J 2010; 10: 1108–17.
81. Claydon VE, Elliott SL, Sheel AW, et al. Cardiovascular responses to vibrostimulation for sperm retrieval in men with spinal cord injury. J Spinal Cord Med 2006; 29: 207–16.
82. Linsenmeyer TA, Culkin D. APS recommendations for the urological evaluation of patients with spinal cord injury. J Spinal Cord Med 1999; 22: 139–42.
83. Gore RM, Mintzer RA, Calenoff L. Gastrointestinal complications of spinal cord injury. Spine (Phila Pa 1976) 1981; 6: 538–44.
84. Cardenas DD, Hooton TM. Urinary tract infection in persons with spinal cord injury. Arch Phys Med Rehabil 1995; 76: 272–80.
85. Albert TJ, Levine MJ, Balderston RA, et al. Gastrointestinal complications in spinal cord injury. Spine (Phila Pa 1976) 1991; 16: S522–5.
86. Hagen EM, Lie SA, Rekand T, et al. Mortality after traumatic spinal cord injury: 50 years of follow-up. J Neurol Neurosurg Psychiatry 2010; 81: 368–73.
87. DiMarco AF, Kowalski KE, Geertman RT, et al. Lower thoracic spinal cord stimulation to restore cough in patients with spinal cord injury: results of a National Institutes of Health sponsored clinical trial. Part II: clinical outcomes. Arch Phys Med Rehabil 2009; 90: 726–32.
88. Strakowski JA, Pease WS, Johnson EW. Phrenic nerve stimulation in the evaluation of ventilator-dependent individuals with C4- and C5-level spinal cord injury. Am J Phys Med Rehabil 2007; 86: 153–7.
89. Merli GJ, Herbison GJ, Ditunno JF, et al. Deep vein thrombosis: prophylaxis in acute spinal cord injured patients. Arch Phys Med Rehabil 1988; 69: 661–4.
90. Myllynen P, Kammonen M, Rokkanen P, et al. Deep venous thrombosis and pulmonary embolism in patients with acute spinal cord injury: a comparison with nonparalyzed patients immobilized due to spinal fractures. J Trauma 1985; 25: 541–3.
91. Green D, Biddle AK, Fahey V, et al. Prevention of thromboembolism in spinal cord injury. Clinical practice guidelines. Consort Spinal Cord Med Paralyzed Vets Am 1997; 1–20.
92. Yarkony GM, Chen D, Palmer J, et al. Management of impotence due to spinal cord injury using low dose papaverine. Paraplegia 1995; 33: 77–9.
93. Teasell RW, Arnold JM, Krassioukov A, et al. Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. Arch Phys Med Rehabil 2000; 81: 506–16.
94. Finerman GA, Stover SL. Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP. Metab Bone Dis Relat Res 1981; 3: 337–42.
95. Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med 1985; 26: 125–32.
96. Schmidt SA, Kjaersgaard-Andersen P, Pedersen NW, et al. The use of indomethacin to prevent the formation of heterotopic bone after total hip replacement. A randomized, double-blind clinical trial. J Bone Joint Surg (Am) 1988; 70: 834–8.
97. Stover SL, Hahn HR, Miller JM. Disodium etidronate in the prevention of heterotopic ossification following spinal cord injury (preliminary report). Paraplegia 1976; 14: 146–56.
98. Hsieh JT, Wolfe DL, Miller WC, et al. Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility. Spinal Cord 2008; 46: 86–95.
99. Maynard FM, Karunas RS, Waring WP. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil 1990; 71: 566–9.
100. Nance P, Schryvers O, Schmidt B, et al. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci 1995; 22: 22–9.
101. Stolp-Smith KA, Wainberg MC. Antidepressant exacerbation of spasticity. Arch Phys Med Rehabil 1999; 80: 339–42.
102. Cardenas DD, Mayo ME. Bacteriuria with fever after spinal cord injury. Arch Phys Med Rehabil 1987; 68: 291–3.
103. Cardenas DD, Moore KN, Dannels-McClure A, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM R 2011; 3: 408–17.
104. Bonica JJ. History of pain concepts and pain therapy. Mt Sinai J Med 1991; 58: 191–202.
105. Anke AG, Stenehjem AE, Stanghelle JK. Pain and life quality within 2 years of spinal cord injury. Paraplegia 1995; 33: 555–9.
106. Cardenas DD, Turner JA, Warms CA, et al. Classification of chronic pain associated with spinal cord injuries. Arch Phys Med Rehabil 2002; 83: 1708–14.
107. Cardenas DD, Warms CA, Turner JA, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002; 96: 365–73.
108. Rintala DH, Holmes SA, Courtade D, et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1547–60.
109. Levendoglu F, Ogun CO, Ozerbil O, et al. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine (Phila Pa 1976) 2004; 29: 743–51.
110. Siddall PJ, Cousins MJ, Otte A, et al. (2006) Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67: 1792–800.
111. Warms CA, Turner JA, Marshall HM, et al. Treatments for chronic pain associated with spinal cord injuries: many are tried, few are helpful. Clin J Pain 2002; 18: 154–63.
112. Rossier AB, Foo D, Shillito J, et al. Posttraumatic cervical syringomyelia. Incidence, clinical presentation, electrophysiological studies, syrinx protein and results of conservative and operative treatment. Brain 1985; 108: 439–61.
113. Schurch B, Wichmann W, Rossier AB. Post-traumatic syringomyelia (cystic myelopathy): a prospective study of 449 patients with spinal cord injury. J Neurol Neurosurg Psychiatry 1996; 60: 61–7.
114. Heldenberg D, Rubinstein A, Levtov O, et al. Serum lipids and lipoprotein concentrations in young quadriplegic patients. Atherosclerosis 1981; 39: 163–7.
115. DeVivo MJ, Krause JS, Lammertse DP. Recent trends in mortality and causes of death among persons with spinal cord injury. Arch Phys Med Rehabil 1999; 80: 1411–19.
116. Bauman WA, Spungen AM. Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism 1994; 43: 749–56.
117. Duckworth WC, Solomon SS, Jallepalli P, et al. Glucose intolerance due to insulin resistance in patients with spinal cord injuries. Diabetes 1980; 29: 906–10.
118. Schmitt JK, Schroeder DL. Endocrine and metabolic consequences of spinal cord injuries. In Lin VW, Cardenas, DD, Cutter NC, et al, eds. Spinal Cord Medicine Principles and Practice. New York, NY: Demos, 2003.
119. van Middendorp JJ, Hosman AJ, Donders AR, et al. A clinical prediction rule for ambulation outcomes after traumatic spinal cord injury: a longitudinal cohort study. Lancet 2011; 377: 1004–10.
120. Zorner B, Blanckenhorn WU, Dietz V, et al. A clinical algorithm for improved prediction of ambulation and patient stratification after incomplete spinal cord injury. J Neurotrauma 2010; 27: 241–52.
121. Bracken MB, Holford TR. Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III. J Neurosurg 2002; 96: 259–66.
122. Waters RL, Adkins RH, Yakura JS, et al. Motor and sensory recovery following incomplete tetraplegia. Arch Phys Med Rehabil 1994; 75: 306–11.
123. Waters RL, Adkins RH, Yakura JS, et al. Motor and sensory recovery following incomplete paraplegia. Arch Phys Med Rehabil 1994; 75: 67–72.
124. Ditunno JF, Stover SL, Freed MM, et al. Motor recovery of the upper extremities in traumatic quadriplegia: a multicenter study. Arch Phys Med Rehabil 1992; 73: 431–6.
125. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet 2002; 359: 417–25.
126. Fawcett JW, Curt A, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007; 45: 190–205.
127. Steeves JD, Kramer JK, Fawcett JW, et al. Extent of spontaneous motor recovery after traumatic cervical sensorimotor complete spinal cord injury. Spinal Cord 2011; 49: 257–65.
128. Whiteneck G, Adler C, Biddle AK, et al. Outcomes following traumatic spinal cord injury: clinical practice guidelines for health-care professionals. Clinical Practice Guidelines. Consort Spinal Cord Med Paralyzed Vets Am 1999; 1–291.
129. Hollar LD. Occupational therapy for physical dysfunction. In Trombly C, ed. Spinal Cord Injury: Clinical Practice Guidelines. Baltimore, MD: Williams and Wilkins, 1995.
130. Waters RL, Sie IH, Gellman H, et al. Functional hand surgery following tetraplegia. Arch Phys Med Rehabil 1996; 77: 86–94.
131. Dietz V. Body weight supported gait training: from laboratory to clinical setting. Brain Res Bull 2009; 78: I–VI.
132. Gorgey AS, Poarch H, Miller J, et al. Locomotor and resistance training restore walking in an elderly person with a chronic incomplete spinal cord injury. Neurorehabilitation 2010; 26: 127–33.
133. Lam T, Pauhl K, Krassioukov A, et al. Using robot-applied resistance to augment body-weight-supported treadmill training in an individual with incomplete spinal cord injury. Phys Ther 2011; 91: 143–51.
134. Phillips SM, Stewart BG, Mahoney DJ, et al. Body-weight-support treadmill training improves blood glucose regulation in persons with incomplete spinal cord injury. J Appl Physiol 2004; 97: 716–24.
135. Soyupek F, Savas S, Ozturk O, et al. Effects of body weight supported treadmill training on cardiac and pulmonary functions in the patients with incomplete spinal cord injury. J Back Musculoskelet Rehabil 2009; 22: 213–18.
136. Dobkin B, Barbeau H, Deforge D, et al. The evolution of walking-related outcomes over the first 12 weeks of rehabilitation for incomplete traumatic spinal cord injury: the multicenter randomized Spinal Cord Injury Locomotor Trial. Neurorehabil Neural Repair 2007; 21: 25–35.
137. North NT. The psychological effects of spinal cord injury: a review. Spinal Cord 1999; 37: 671–9.
138. Folkman S. Personal control and stress and coping processes: a theoretical analysis. J Pers Soc Psychol 1984; 46: 839–52.
139. Galvin LR, Godfrey HP. The impact of coping on emotional adjustment to spinal cord injury (SCI): review of the literature and application of a stress appraisal and coping formulation. Spinal Cord 2001; 39: 615–27.
140. Kennedy P, Duff J, Evans M, et al. Coping effectiveness training reduces depression and anxiety following traumatic spinal cord injuries. Br J Clin Psychol 2003; 42: 41–52.
141. Kennedy P, Duff J. Post traumatic stress disorder and spinal cord injuries. Spinal Cord 2001; 39: 1–10.
142. Stiens SA, Bergman SB, Formal CS. Spinal cord injury rehabilitation. 4. Individual experience, personal adaptation, and social perspectives. Arch Phys Med Rehabil 1997; 78: S65–72.
143. Post MW, de Witte LP, van Asbeck FW, et al. Predictors of health status and life satisfaction in spinal cord injury. Arch Phys Med Rehabil 1998; 79: 395–401.
144. Putzke JD, Richards JS, Hicken BL, et al. Predictors of life satisfaction: a spinal cord injury cohort study. Arch Phys Med Rehabil 2002; 83: 555–61.
145. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322: 1405–11.
146. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. JAMA 1997; 277: 1597–1604.
147. Bracken MB, Holford TR. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg 1993; 79: 500–7.
148. Lee HC, Cho DY, Lee WY, et al. Pitfalls in treatment of acute cervical spinal cord injury using high-dose methylprednisolone: a retrospect audit of 111 patients. Surg Neurol 2007; 68: S37–41.
149. Citerio G, Cormio M, Sganzerla EP. [Steroids in acute spinal cord injury. An unproven standard of care]. Minerva Anestesiol 2002; 68: 315–20.
150. Hurlbert RJ. The role of steroids in acute spinal cord injury: an evidence-based analysis. Spine (Phila Pa 1976) 2001; 26: S39–46.
151. Dobkin B, Apple D, Barbeau H, et al. Methods for a randomized trial of weight-supported treadmill training versus conventional training for walking during in patient rehabilitation after incomplete traumatic spinal cord injury. Rehabil Neural Repair 2003; 17: 153–67.
152. Hulsebosch CE, Hains BC, Waldrep K, et al. Bridging the gap: from discovery to clinical trials in spinal cord injury. J Neurotrauma 2000; 17: 1117–28.
153. Barbeau H. Locomotor training in neurorehabilitation: emerging rehabilitation concepts. Neurorehabil Neural Repair 2003; 17: 3–11.
154. Protas EJ, Holmes SA, Qureshy H, et al. Supported treadmill ambulation training after spinal cord injury: a pilot study. Arch Phys Med Rehabil 2001; 82: 825–31.
155. Wernig A, Muller S, Nanassy A, et al. Laufband therapy based on ‘rules of spinal locomotion’ is effective in spinal cord injured persons. Eur J Neurosci 1995; 7: 823–9.
156. Wernig A, Nanassy A, Muller S. Maintenance of locomotor abilities following Laufband (treadmill) therapy in para- and tetraplegic persons: follow-up studies. Spinal Cord 1998; 36: 744–9.
157. Barbeau H, Norman KE. The effect of noradrenergic drugs on the recovery of walking after spinal cord injury. Spinal Cord 2003; 41: 137–43.
158. Dobkin BH, Apple D, Barbeau H, et al. Methods for a randomized trial of weight-supported treadmill training versus conventional training for walking during inpatient rehabilitation after incomplete traumatic spinal cord injury. Neurorehabil Neural Repair 2003; 17: 153–67.
159. Kirshblum S. New rehabilitation interventions in spinal cord injury. J Spinal Cord Med 2004; 27: 342–50.
160. Field-Fote EC. Spinal cord control of movement: implications for locomotor rehabilitation following spinal cord injury. Phys Ther 2000; 80: 477–84.
161. Prochazka A, Mushahwar V, Yakovenko S. Activation and coordination of spinal motoneuron pools after spinal cord injury. Prog Brain Res 2002; 137: 109–24.
162. Wolpaw JR, Tennissen AM. Activity-dependent spinal cord plasticity in health and disease. Ann Rev Neurosci 2001; 24: 807–43.
163. Donovan-Hall MK, Burridge J, Dibb B, et al. The views of people with spinal cord injury about the use of functional electrical stimulation. Artif Organs 2011; 35: 204–11.
164. Field-Fote EC. Combined use of body weight support, functional electric stimulation, and treadmill training to improve walking ability in individuals with chronic incomplete spinal cord injury. Arch Phys Med Rehabil 2001; 82: 818–24.
165. Kapadia NM, Zivanovic V, Furlan JC, et al. Functional electrical stimulation therapy for grasping in traumatic incomplete spinal cord injury: randomized control trial. Artif Organs 2011; 35: 212–16.
166. Leeb R, Gubler M, Tavella M, et al. On the road to a neuroprosthetic hand: a novel hand grasp orthosis based on functional electrical stimulation. Conf Proc IEEE Eng Med Biol Soc 2010: 146–9.
167. Thrasher TA, Popovic MR. Functional electrical stimulation of walking: function, exercise and rehabilitation. Ann Readapt Med Phys 2008; 51: 452–60.
168. Creasey GH, Ho CH, Triolo RJ, et al. Clinical applications of electrical stimulation after spinal cord injury. J Spinal Cord Med 2004; 27: 365–75.
169. Rupp R, Gerner HJ. Neuroprosthetics of the upper extremity – clinical application in spinal cord injury and future perspectives. Biomed Tech (Berl) 2004; 49: 93–8.
170. Mulcahey MJ, Betz RR, Kozin SH, et al. Implantation of the Freehand System during initial rehabilitation using minimally invasive techniques. Spinal Cord 2004; 42: 146–55.
171. Davis SE, Mulcahey MJ, Smith BT, et al. Self-reported use of an implanted FES hand system by adolescents with tetraplegia. J Spinal Cord Med 1998; 21: 220–26.
172. Taylor P, Esnouf J, Hobby J. Pattern of use and user satisfaction of neuro-control freehand system. Spinal Cord 2001; 39: 156–60.
173. Taylor P, Esnouf J, Hobby J. The functional impact of the Freehand System on tetraplegic hand function. Clinical results. Spinal Cord 2002; 40: 560–6.
174. Peckham PH, Keith MW, Kilgore KL, et al. Efficacy of an implanted neuroprosthesis for restoring hand grasp in tetraplegia: a multicenter study. Arch Phys Med Rehabil 2001; 82: 1380–8.
175. Glaser RM. Physiology of functional electrical stimulation-induced exercise: basic science perspective. J Neurol Rehabil 1991; 5: 49–61.
176. Gormann PH. Functional electrical stimulation. In Lin VW, Cardenas DD, Cutter NC, et al., eds. Spinal Cord Medicine, Principles and Practice. New York, NY: Demos, 2003.
177. Johnston TE, Finson RL, Smith BT, et al. Functional electrical stimulation for augmented walking in adolescents with incomplete spinal cord injury. J Spinal Cord Med 2003; 26: 390–400.
178. Spadone R, Merati G, Bertocchi E, et al. Energy consumption of locomotion with orthosis versus Parastep-assisted gait: a single case study. Spinal Cord 2003; 41: 97–104.
179. Winchester P, Carollo JJ, Habasevich R. Physiologic costs of reciprocal gait in FES assisted walking. Paraplegia 1994; 32: 680–6.
180. Brindley GS. The first 500 patients with sacral anterior root stimulator implants: general description. Paraplegia 1994; 32: 795–805.
181. Creasey GH, Dahlberg JE. Economic consequences of an implanted neuroprosthesis for bladder and bowel management. Arch Phys Med Rehabil 2001; 82: 1520–25.
182. Creasey GH, Grill JH, Korsten M, et al. An implantable neuroprosthesis for restoring bladder and bowel control to patients with spinal cord injuries: a multicenter trial. Arch Phys Med Rehabil 2001; 82: 1512–9.
183. Kachourbos MJ, Creasey GH. Health promotion in motion: improving quality of life for persons with neurogenic bladder and bowel using assistive technology. Sci Nurs 2000; 17: 125–9.
184. Martens FM, den Hollander PP, Snoek GJ, et al. Quality of life in complete spinal cord injury patients with a Brindley bladder stimulator compared to a matched control group. Neurourol Urodyn 2011; 30: 551–5.
185. Kutzenberger J, Domurath B, Sauerwein D. Spastic bladder and spinal cord injury: seventeen years of experience with sacral deafferentation and implantation of an anterior root stimulator. Artif Organs 2005; 29: 239–41.
186. Burks FN, Bui DT, Peters KM. Neuromodulation and the neurogenic bladder. Urol Clin North Am 2010; 37: 559–65.
187. Robin S, Sawan M, Abdel-Gawad M, et al. Implantable stimulation system dedicated for neural selective stimulation. Med Biol Eng Comput 1998; 36: 490–2.
188. Blight AR. Axonal physiology of chronic spinal cord injury in the cat: intracellular recording in vitro. Neuroscience 1983; 10: 1471–86.
189. McDonald JW, Becker D, Sadowsky CL, et al. Late recovery following spinal cord injury. Case report and review of the literature. J Neurosurg 2002; 97: 252–65.
190. Britell CW, Hammond MC. Spinal cord injury. In Hays RM, Kraft GH, Stolov WC, eds. Chronic Disease and Disability. New York, NY: Demos Medical Publishing, 1994; 144.

References

1. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010; 9: 520–32.
2. Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9: 727–39.
3. Grytten Torkildsen N, Lie SA, Aarseth JH, et al. Nyland H, Myhr KM. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008; 14: 1191–8.
4. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71: 129–35.
5. Bentzen J, Flachs EM, Stenager E, et al. Prevalence of multiple sclerosis in Denmark 1950–2005. Mult Scler 2010; 16: 520–5.
6. Koutsis G, Evangelopoulos ME, Andreadou E, et al. The onset of multiple sclerosis in Greece: a single-center study of 1,034 consecutive patients. Eur Neurol 2010; 63: 350–6.
7. Sahraian MA, Khorramnia S, Ebrahim MM, et al. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol 2010; 64: 331–6.
8. Banwell B, Ghezzi A, Bar-Or A, et al. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007; 6: 887–902.
9. Martinelli V, Rodegher M, Moiola L, et al. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004; 25: S350–5.
10. Alonso-Magdalena L, Romero-Pinel L, Moral E, et al. Anticipation of age at onset in multiple sclerosis: methodologic pitfalls. Acta Neurol Scand 2010; 121: 426–8.
11. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9: 599–612.
12. Levin LI, Munger KL, O'Reilly EJ, et al. Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67: 824–30.
13. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502–17.
14. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep 2007; 7: 239–44.
15. Hurwitz BJ. Analysis of current multiple sclerosis registries. Neurology 2011; 76: S7–13.
16. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6: 903–12.
17. Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005; 4: 643–52.
18. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–7.
19. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the “McDonald criteria.” Ann Neurol 2011; 69: 292–302.
20. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008; 7: 615–25.
21. Swanton JK, Fernando K, Dalton CM, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 830–3.
22. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007; 6: 677–86.
23. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis. Part 1. Early pension and temporary unemployment–a historical prospective cohort study. Mult Scler 2010; 16: 121–6.
24. Pfleger CC, Flachs EM, Koch-Henriksen N. Social consequences of multiple sclerosis. Part 2. Divorce and separation: a historical prospective cohort study. Mult Scler 2010; 16: 878–82.
25. Kesselring J. Disease progression in multiple sclerosis. I. Impaired mobility and its impact on limitations of activities and social participation. Eur Neurol Rev 2010; 5: 56–60.
26. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77: 918–26.
27. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006; 66: 1696–702.
28. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005; 11: 232–9.
29. Rose AS, Kuzma JW, Kurtzke JF, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo. Final report. Neurology 1970; 20: 1–59.
30. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511–16.
31. Compston DAS, Milligan NM, Hughes PJ, et al. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry 1987; 50: 517–22.
32. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005; 11: 425–32.
33. Sellebjerg F, Frederiksen JL, Nielsen PM, et al. Double- blind, randomized. placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529–34.
34. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol 2008; 28: 56–68.
35. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987–97.
36. Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011; 76: S14–25.
37. Rieckmann P, Traboulsee A, Devonshire V, et al. Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord 2008; 1: 181–92.
38. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.
39. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–15.
40. Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 2011; 76: S26–34.
41. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 2009; 8: 254–60.
42. Paltamaa J, Sarasoja T, Wikstrom J, et al. Physical functioning in multiple sclerosis: a population-based study in central Finland. J Rehabil Med 2006; 38: 339–45.
43. Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler 2010; 16: 816–28.
44. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol 2010; 9: 1182–99.
45. Kesselring J. Complications of multiple sclerosis: fatigue; spasticity; ataxia; pain; and bowel, bladder, and sexual dysfunction. In McDonald WI, Noseworthy JH, eds. Multiple Sclerosis 2. 1st edn. Philadelphia, PA: Butterworth–Heinemann, 2003; 217–27.
46. Khan F, Gray O. Disability management and rehabilitation for persons with multiple sclerosis. Neural Regen Res 2010; 4: 301–9.
47. Erwin A, Gudesblatt M, Bethoux F, et al. Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler 2011; 17: 623–9.
48. Stetkarova I, Yablon SA, Kofler M, et al. Procedure- and device-related complications of intrathecal baclofen administration for management of adult muscle hypertonia: a review. Neurorehabil Neural Repair 2010; 24: 609–19.
49. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707–12.
50. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004; 218: 103–8.
51. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev 2007; 1: CD005029.
52. Yap L, Kouyialis A, Varma TR. Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? Br J Neurosurg 2007; 21: 349–54.
53. Timmermann L, Deuschl G, Fogel W, et al. [Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association]. Nervenarzt 2009; 80: 673–7.
54. Judge SI, Bever CT. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006; 111: 224–59.
55. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732–8.
56. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001; 7: 354–8.
57. Kos D, Kerckhofs E, Nagels G, et al. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 2008; 22: 91–100.
58. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72: 179–83.
59. Lange R, Volkmer M, Heesen C, et al. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 2009; 256: 645–50.
60. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 2010; 44: 1098–103.
61. Littleton ET, Hobart JC, Palace J. Modafinil for multiple sclerosis fatigue: does it work? Clin Neurol Neurosurg 2010; 112: 29–31.
62. Pucci E, Branas P, D'Amico R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007; 1: CD002818.
63. MacAllister WS, Krupp LB. Multiple sclerosis-related fatigue. Phys Med Rehabil Clin N Am 2005; 16: 483–502.
64. Khan F, Pallant JF, Shea TL, et al. Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort. Disabil Rehabil 2009; 31: 1567–76.
65. Khan F, Pallant JF, Pallant JI, et al. A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 1033–8.
66. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 470–7.
67. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007; 62: 452–7.
68. Mehnert U, Birzele J, Reuter K, et al. The effect of botulinum toxin type A on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol 2010; 184: 1011–16.
69. Jepson RG, Mihaljevic L, Craig J. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev 2004; 2: CD001321.
70. Nortvedt MW, Riise T, Frugard J, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler 2007; 13: 106–12.
71. Zorzon M, Zivadinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: a case-control study: I. Frequency and comparison of groups. Mult Scler 1999; 5: 418–27.
72. Zivadinov R, Zorzon M, Bosco A, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999; 5: 428–31.
73. Foley FW, LaRocca NG, Sanders AS, et al. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler 2001; 7: 417–21.
74. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–404.
75. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003; 63: 153–66.
76. Vidal J, Curcoll L, Roig T, et al. Intracavernous pharmacotherapy for management of erectile dysfunction in multiple sclerosis patients. Rev Neurol 1995; 23: 269–71.
77. Khan F, Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics, and impact on quality of life in an Australian community cohort. J Pain 2007; 8: 614–23.
78. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol 2008; 7: 1139–51.
79. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579–85.
80. Christodoulou C, Melville P, Scherl WF, et al. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006; 245: 127–36.
81. Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003; 61: 1524–7.
82. D'Alisa S, Miscio G, Baudo S, et al. Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil 2006; 28: 307–14.
83. Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2011; 2: CD007295.
84. Thompson A. The effectiveness of neurological rehabilitation in multiple sclerosis. J Rehabil Res Dev 2000; 37: 455–61.
85. Khan F, Turner-Stokes L, Ng L, et al. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev 2007; 2: CD006036.
86. Craig J, Young CA, Ennis M, et al. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosug Psychiatry 2003; 74: 1225–30.
87. Liu C, Playford ED, Thompson AJ. Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis? J Neurol 2003; 250: 1214–18.
88. Langdon DW, Thompson AJ. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult Scler 1999; 5: 94–100.
89. Grasso MG, Troisi E, Rizzi F, et al. Prognostic factors in multidisciplinary rehabilitation treatment in multiple sclerosis: an outcome study. Mult Scler 2005; 11: 719–24.
90. Uhthoff W. Untersuchungen über die bei der multiplen Herdsklerose vorkommenden Augenstörungen. Arch Psychiat Nervenkr 1890; 21: 303–410.
91. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1649–73.
92. Humm AM, Beer S, Kool J, et al. Quantification of Uhthoff's phenomenon in multiple sclerosis: a magnetic stimulation study. Clin Neurophysiol 2004; 115: 2493–501.
93. Sheean GL, Murray NMF, Rothwell JC, et al. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997; 120: 299–315.
94. Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler 2008; 14: 35–53.
95. Smith RM, Adeney-Steel M, Fulcher G, et al. Symptom change with exercise is a temporary phenomenon for people with multiple sclerosis. Arch Phys Med Rehabil 2006; 87: 723–7.
96. Bjarnadottir OH, Konradsdottir AD, Reynisdottir K, et al. Multiple sclerosis and brief moderate exercise. A randomised study. Mult Scler 2007; 13: 776–82.
97. Rocca MA, Falini A, Colombo B, et al. Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Ann Neurol 2002; 51: 330–9.
98. Cifelli A, Matthews PM. Cerebral plasticity in multiple sclerosis: insights from fMRI. Mult Scler 2002; 8: 193–9.
99. Thickbroom GW, Sacco P, Faulkner DL, et al. Enhanced corticomotor excitability with dynamic fatiguing exercise of the lower limb in multiple sclerosis. J Neurol 2008; 255: 1001–5.
100. Penner IK, Opwis K, Kappos L. Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis. J Neurol 2007; 254: 1153–7.
101. Heesen C, Romberg A, Gold S, et al. Physical exercise in multiple sclerosis: supportive care or a putative disease-modifying treatment. Expert Rev Neurother 2006; 6: 347–55.
102. Freeman JA, Langdon DW, Hobart JC, et al. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 1999; 52: 50–6.
103. World Health Organization (WHO). Comunity based rehabilitation. WHO library joint position paper, 2004.
104. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability rating scale (EDSS). Neurology 1983; 13: 1444–52.
105. Twork S, Wiesmeth S, Spindler M, et al. Disability status and quality of life in multiple sclerosis: non-linearity of the expanded disability status scale (EDSS). Health Qual Life Outcomes 2010; 8: 55.
106. van Winsen LM, Kragt JJ, Hoogervorst EL, et al. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Mult Scler 2010; 16: 604–10.
107. Cadavid D, Tang Y, O'Neill G. Responsiveness of the expanded disability status scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol 2010; 51: 321–9.
108. Hobart J, Kalkers N, Barkhof F, et al. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 41–6.
109. World Health Organization (WHO). International Classification of Functioning, Disability and Health. Geneva: WHO, 2001.
110. Kesselring J, Coenen M, Cieza A, et al. Developing the ICF core sets for multiple sclerosis to specify functioning. Mult Scler 2008; 14: 252–4.
111. Holper L, Coenen M, Weise A, et al. Characterization of functioning in multiple sclerosis using the ICF. J Neurol 2010; 257: 103–13.
112. Khan F, Pallant JF, Brand C, et al. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79: 1230–5.
113. Khan F, Turner-Stokes L, Stevermuer T, et al. Multiple sclerosis rehabilitation outcomes: analysis of a national casemix data set from Australia. Mult Scler 2009; 15: 869–75.
114. Storr LK, Sorensen PS, Ravnborg M. The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Mult Scler 2006; 12: 235–42.
115. Motl RW, McAuley E, Snook EM. Physical activity and multiple sclerosis: a meta-analysis. Mult Scler 2005; 11: 459–63.
116. Motl RW, Snook EM, McAuley E, et al. Demographic correlates of physical activity in individuals with multiple sclerosis. Disabil Rehabil 2007; 29: 1301–4.
117. Doerksen SE, Motl RW, McAuley E. Environmental correlates of physical activity in multiple sclerosis: a cross-sectional study. Int J Behav Nutr Phys Act 2007; 4: 49.
118. Stuifbergen AK, Blozis SA, Harrison TC, et al. Exercise, functional limitations, and quality of life: a longitudinal study of persons with multiple sclerosis. Arch Phys Med Rehabil 2006; 87: 935–43.
119. Solari A, Filippini G, Gasco P, et al. Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 1999; 52: 57–62.
120. Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 174–9.
121. Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler 2008; 14: 35–53.
122. Rietberg MB, Brooks D, Uitdehaag BM, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev 2005; 1: CD003980.
123. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432–41.
124. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002; 8: 161–8.
125. Dalgas U, Stenager E, Jakobsen J, et al. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 2009; 73: 1478–84.
126. Dalgas U, Stenager E, Jakobsen J, et al. Muscle fiber size increases following resistance training in multiple sclerosis. Mult Scler 2010; 16: 1367–76.
127. Rasova K, Havrdova E, Brandejsky P, et al. Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. Mult Scler 2006; 12: 227–34.
128. Rampello A, Franceschini M, Piepoli M, et al. Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study. Phys Ther 2007; 87: 545–55.
129. van den Berg M, Dawes H, Wade DT, et al. Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. J Neurol Neurosurg Psychiatry 2006; 77: 531–3.
130. Giesser B, Beres-Jones J, Budovitch A, et al. Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler 2007; 13: 224–31.
131. Newman MA, Dawes H, van den Berg M, et al. Can aerobic treadmill training reduce the effort of walking and fatigue in people with multiple sclerosis: a pilot study. Mult Scler 2007; 13: 113–19.
132. Beer S, Aschbacher B, Manoglou D, et al. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. Mult Scler 2008; 14: 231–6.
133. Husemann B, Muller F, Krewer C, et al. Effects of locomotion training with assistance of a robot-driven gait orthosis in hemiparetic patients after stroke: a randomized controlled pilot study. Stroke 2007; 38: 349–54.
134. McAuley E, Motl RW, Morris KS, et al. Enhancing physical activity adherence and well-being in multiple sclerosis: a randomised controlled trial. Mult Scler 2007; 13: 652–9.
135. Künzle U. Schweizer Studie über die Wirksamkeit der Hippotherapie-K bei Multiple-Sklerose-Patienten. Hippotherapie. Berlin: Springer, 2000; 359–81.
136. Bronson C, Brewerton K, Ong J, et al. Does hippotherapy improve balance in persons with multiple sclerosis: a systematic review. Eur J Phys Rehabil Med 2010; 46: 347–53.
137. Silkwood-Sherer D, Warmbier H. Effects of hippotherapy on postural stability, in persons with multiple sclerosis: a pilot study. J Neurol Phys Ther 2007; 31: 77–84.
138. Gamper UN. Wasserspezifische Bewegungstherapie und Training. Stuttgart: Gustav Fischer Verlag, 1995.
139. Kesiktas N, Paker N, Erdogan N, et al. The use of hydrotherapy for the management of spasticity. Neurorehabil Neural Repair 2004; 18: 268–73.
140. Salem Y, Scott AH, Karpatkin H, et al. Community-based group aquatic programme for individuals with multiple sclerosis: a pilot study. Disabil Rehabil 2011; 33: 720–8.
141. Beenakker EA, Oparina TI, Hartgring A, et al. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology 2001; 57: 892–4.
142. White AT, Wilson TE, Davis SL, et al. Effect of precooling on physical performance in multiple sclerosis. Mult Scler 2000; 6: 176–80.
143. Meyer-Heim A, Rothmaier M, Weder M, et al. Advanced lightweight cooling-garment technology: functional improvements in thermosensitive patients with multiple sclerosis. Mult Scler 2007; 13: 232–7.
144. Steultjens EM, Dekker J, Bouter LM, et al. Occupational therapy for multiple sclerosis. Cochrane Database Syst Rev 2003; 3: CD003608.
145. Baker NA, Tickle-Degnen L. The effectiveness of physical, psychological, and functional interventions in treating clients with multiple sclerosis: a meta-analysis. Am J Occup Ther 2001; 55: 324–31.
146. Maitra K, Hall C, Kalish T, et al. Five-year retrospective study of inpatient occupational therapy outcomes for patients with multiple sclerosis. Am J Occup Ther 2010; 64: 689–94.
147. Mathiowetz VG, Finlayson ML, Matuska KM, et al. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler 2005; 11: 592–601.
148. Bartholome G. Schluckstörungen. In Frommelt P, Grotzbach H, eds. Neurorehabilitation. Berlin Wien: Blackwell Wissenschafts-Verlag, 1999; 107–24.
149. Prosiegel M, Heintze M, Wagner-Sonntag E, et al. Schluckstörungen bei neurologischen Patienten: Eine prospektive Studie zu Diagnostik, Störungsmustern, Therapie und Outcome. Nervenarzt 2002; 73: 364–70.
150. Gosselink R, Kovacs L, Ketelaer P, et al. Respiratory muscle weakness and respiratory muscle training in severely disabled multiple sclerosis patients. Arch Phys Med Rehabil 2000; 81: 747–51.
151. Vahtera T, Haaranen M, Viramo-Koskela AL, et al. Pelvic floor rehabilitation is effective in patients with multiple sclerosis. Clin Rehabil 1997; 11: 211–19.
152. Dasgupta P, Haslam C, Goodwin R, et al. The ‘Queen Square bladder stimulator’: a device for assisting emptying of the neurogenic bladder. Br J Urol 1997; 80: 234–7.
153. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003; 17: 42–7.
154. O'Brien AR, Chiaravalloti N, Goverover Y, et al. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 2008; 89: 761–9.
155. Mattioli F, Stampatori C, Bellomi F, et al. Neuropsychological rehabilitation in adult multiple sclerosis. Neurol Sci 2010; 31: S271–4.
156. Benedict RH, Shapiro A, Priore R, et al. Neuropsychological counseling improves social behavior in cognitively-impaired multiple sclerosis patients. Mult Scler 2000; 6: 391–6.
157. Lincoln NB, Dent A, Harding J, et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 93–8.
158. Thomas PW, Thomas S, Hillier C, et al. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006; 1: CD004431.
159. Forman AC, Lincoln NB. Evaluation of an adjustment group for people with multiple sclerosis: a pilot randomized controlled trial. Clin Rehabil 2010; 24: 211–21.
160. Freeman J, Allison R. Group exercise classes in people with multiple sclerosis: a pilot study. Physiother Res Int 2004; 9: 104–7.
161. Khan F, Ng L, Turner-Stokes L. Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis. Cochrane Database Syst Rev 2009; 1: CD007256.
162. Freeman J, Ford H, Mattison P, et al. Developing MS healthcare standards: evidence-based recommendations for service providers. MS Soc GB N Irl MS Prof Netw 2002; 1–37.
163. Feigenson JS, Scheinberg L, Catalano M, et al. The cost-effectiveness of multiple sclerosis rehabilitation: a model. Neurology 1981; 31: 1316–22.
164. Greenspun B, Stineman M, Agri R. Multiple sclerosis and rehabilitation outcome. Arch Phys Med Rehabil 1987; 68: 434–7.
165. Francabandera FL, Holland NJ, Wiesel-Levison P, et al. Multiple sclerosis rehabilitation: inpatient vs. outpatient. Rehabil Nurs 1988; 13: 251–3.
166. LaRocca MG, Kalb RC. Efficacy of rehabilitation in multiple sclerosis. J Neurol Rehabil 1992; 6: 147–55.
167. Kidd D, Thompson AJ. Prospective study of neurorehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 62: 423–4.
168. Aisen ML, Sevilla D, Fox N. Inpatient rehabilitation for multiple sclerosis. J Neurol Rehabil 1996; 10: 43–6.
169. Freeman JA, Langdon DW, Hobart JC, et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997; 42: 236–44.
170. Di Fabio RP, Soderberg J, Choi T, et al. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil 1998; 79: 141–6.
171. Patti F, Ciancio MR, Cacopardo M, et al. Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients–a randomised controlled trial. J Neurol 2003; 250: 861–6.

References

1. Simmons Z, Bremer BA, Robbins RA, et al. Quality of life in ALS depends on factors other than strength and physical function. Neurology 2000; 55: 388–92.
2. Padua L, Evoli A, Aprile I, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001; 22: 363–9.
3. Amosun SL, Ikuesan BA, Oloyede IJ. Rehabilitation of the handicapped child–what about the caregiver? PNG Med J 1995; 38: 208–14.
4. Mitsumoto H, Del Bene M. Improving the quality of life for people with ALS: the challenge ahead. Amyotroph Lateral Scler 2000; 1: 329–36.
5. Bromberg MB, Forshew DA. Comparison of instruments addressing quality of life in patients with ALS and their caregivers. Neurology 2002; 58: 320–2.
6. White C, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database Syst Rev 2004; 4: CD003904.
7. Abresch RT, Jensen MP, Carter GT. Health-related quality of life in peripheral neuropathy. Phys Med Rehabil Clin N Am 2001; 12: 461–72.
8. Abresch RT, Seyden NK, Wineinger MA. Quality of life. Issues for persons with neuromuscular diseases. Phys Med Rehabil Clin N Am 1998; 9: 233–48.
9. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2000; 1: 293–9.
10. Kühnlein P, Gdynia HJ, Sperfeld AD, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol 2008; 4: 366–74.
11. Donaghy M. Classification and clinical features of motor neurone diseases and motor neuropathies in adults. J Neurol 1999; 246: 331–3.
12. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10: S2–9.
13. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neurone disease. J Neurol Neurosurg Psychiatry 2003; 74: iv32–47.
14. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006; 7: 710–23.
15. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009; 65: S3–9.
16. Tripathi VB, Al-Chalabi A. Molecular insights and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 2008; 7: 11–19.
17. Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004; 427: 801.
18. Shook SJ, Pioro EP. Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient. Ann Neurol 2009; 65: S10–16.
19. Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2010; 10: 53–7.
20. Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2002; 2: CD001447.
21. Radunović A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007; 6: 913–25.
22. Meininger V, Drory VE, Leigh PN, et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009; 10: 378–83.
23. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2002; 3: CD002064.
24. Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009; 66: 227–34.
25. Sorenson EJ, Windbank AJ, Mandrekar JN, et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008; 71: 1770–5.
26. Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–45.
27. Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10: 481–90.
28. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008; 105: 2052–7.
29. Chiò A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 2010; 75: 619–25.
30. Christensen PB, Hojer-Pedersen E, Jensen NB. Survival of patients with myotrophic lateral sclerosis in 2 Danish counties. Neurology 1990; 40: 600–4.
31. Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler 2003; 4: 136–43.
32. Norquist JM, Jenkinson C. Fitzpatrick R, et al. Factors which predict physical and mental health status in patients with amyotrophic lateral sclerosis over time. Amyotroph Lateral Scler 2003; 4: 112–17.
33. McCluskey L. Palliative rehabilitation and amyotrophic lateral sclerosis: a perfect match. Neurorehabilitation 2007; 22: 407–8.
34. Brooks BR. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol 2009; 65: S17–23.
35. Chiò A, Cucatto A, Calvo A, et al. Amyotrophic lateral sclerosis among the migrant population to Piemonte, northwestern Italy. J Neurol 1999; 246: 175–80.
36. Miller RG, Anderson FA, Bradley WG, et al. The ALS patient care database: goals, design, and early results. Neurology 2000; 54: 53–7.
37. van den Berg JP, Kalmijn S, Lindeman E, et al. Rehabilitation care for patients with ALS in the Netherlands. Amyotroph Lateral Scler 2003; 4: 186–90.
38. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry 2003; 74: 1258–61.
39. Chiò A, Finocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology 1999; 53: 1123–5.
40. Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler 2003; 4: 177–85.
41. McKim DA, Road J, Avendano M, et al. Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011; 18: 197–215.
42. Miller RG, Jackson CE, Kasarskis EJ, et al. The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology 2009; 73: 1218–26.
43. Miller RG, Jackson CE, Kasarskis EJ, et al. The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology 2009; 73: 1227–33.
44. Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2004; 1: CD004156.
45. Drory VE, Goltsman E, Reznik JG, et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 133–7.
46. Trail M, Nelson N, Van JN, et al. Wheelchair use by patients with amyotrophic lateral sclerosis: a survey of user characteristics and selection preferences. Arch Phys Med Rehabil 2001; 82: 98–102.
47. Abresch RT, Carter GT, Jensen MP, et al. Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. Am J Hosp Palliat Care 2002; 19: 39–48.
48. Shibata M, Abe K, Jimbo A, et al. Complex regional pain syndrome type I associated with amyotrophic lateral sclerosis. Clin J Pain 2003; 19: 69–70.
49. Kiebert GM, Green C, Murphy C, et al. Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 87–93.
50. Maillot F, Laueriere L, Hazouard E, et al. Quality of life in ALS is maintained as physical function declines. Neurology 2001; 57: 1939.
51. Pasetti C, Zanini G. The physician–patient relationship in amyotrophic lateral sclerosis. Neurol Sci 2000; 21: 318–23.
52. Carter GT, Bednar-Butler LM, Abresch RT, et al. Expanding the role of hospice care in amyotrophic lateral sclerosis. Am J Hosp Palliat Care 1999; 16: 707–10.
53. Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol 2011; 68: 979–84.
54. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008; 371: 2120–33.
55. Zerres K, Wirth B, Rudnik-Schoneborn S. Spinal muscular atrophy–clinical and genetic correlations. Neuromusc Disord 1997; 7: 202–7.
56. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15: 228–37.
57. Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003; 60: 1601–03.
58. Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12: 2481–9.
59. Katsuno M, Banno H, Suzuki K, et al. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy. Arch Neurol 2012; 69: 436–40.
60. Prior TW, Russman BS. Spinal muscular atrophy. In Pagon RA, Bird TD, Dolan CR, et al, eds. GeneReviews [Internet]. Seattle: University of Washington, 2000.
61. Ryan MM. The use of invasive ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion against. Paediatr Respir Rev 2008; 9: 51–4.
62. Fehlings DL, Kirsch S, McComas A, et al. Evaluation of therapeutic electrical stimulation to improve muscle strength and function in children with types II/III spinal muscular atrophy. Dev Med Child Neurol 2002; 44: 741–4.
63. McDonald CM. Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. Phys Med Rehabil Clin N Am 1998; 9: 187–211.
64. Kroksmark AK, Beckung E, Tulinius M. Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. Eur J Paediatr Neurol 2001; 5: 191–8.
65. Steffensen BF, Lyager S, Werge B, et al. Physical capacity in non-ambulatory people with Duchenne muscular dystrophy or spinal muscular atrophy: a longitudinal study. Dev Med Child Neurol 2002; 44: 623–32.
66. Koessler W, Wanke T, Winkler G, et al. 2 years' experience with inspiratory muscle training in patients with neuromuscular disorders. Chest 2001; 120: 765–9.
67. Lissoni A, Aliverti A, Tzeng AC, et al. Kinematic analysis of patients with spinal muscular atrophy during spontaneous breathing and mechanical ventilation. Am J Phys Med Rehabil 1998; 77: 188–92.
68. Robinson D, Galasko CS, Delaney C, et al. Scoliosis and lung function in spinal muscular atrophy. Eur Spine J 1995; 4: 268–73.
69. Bach JR, Zhitnikov S. The management of neuromuscular ventilatory failure. Semin Pediatr Neurol 1998; 5: 92–105.
70. Hardart MK, Burns JP, Truog RD. Respiratory support in spinal muscular atrophy type I: a survey of physician practices and attitudes. Pediatrics 2002; 110: e24.
71. Willig TN, Paulus J, Lacau Saint Guily J, et al. Swallowing problems in neuromuscular disorders. Arch Phys Med Rehabil 1994; 75: 1175–81.
72. Billard C, Gillet P, Barthez M, et al. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev Med Child Neurol 1998; 40: 12–20.
73. Fowler WM, Abresch RT, Koch TR, et al. Employment profiles in neuromuscular diseases. Am J Phys Med Rehabil 1997; 76: 26–37.
74. Mulder DW. Clinical observations on acute poliomyelitis. Ann N Y Acad Sci 1995; 753: 1–10.
75. Bruno RL. Paralytic vs. nonparalytic polio: distinction without a difference? Am J Phys Med Rehabil 2000; 79: 4–12.
76. Dalakas MC. Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 1995; 753: 167–85.
77. Farbu E, Gilhus NE, Barnes MP, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006; 13: 795–801.
78. Jubelt B. Post-polio syndrome. Curr Treat Options Neurol 2004; 6: 87–93.
79. Sunnerhagen KS, Grimby G. Muscular effects in late polio. Acta Physiol Scand 2001; 171: 335–40.
80. Farbu E, Gilhus NE. Education, occupation, and perception of health amongst previous polio patients compared to their siblings. Eur J Neurol 2002; 9: 233–41.
81. Farbu E, Rekand T, Gilhus NE. Post-polio syndrome and total health status in a prospective hospital study. Eur J Neurol 2003; 10: 407–13.
82. Rekand T, Korv J, Farbu E, et al. Long-term outcome after poliomyelitis in different health and social conditions. J Epidemiol Commun Health 2003; 57: 368–72.
83. Schanke AK, Lobben B, Oyhaugen S. The Norwegian polio study 1994 part II: early experiences of polio and later psychosocial well-being. Spinal Cord 1999; 37: 515–21.
84. Kling C, Persson A, Gardulf A. The ADL ability and use of technical aids in persons with late effects of polio. Am J Occup Ther 2002; 56: 457–61.
85. Nollet F, Beelen A, Twisk JW, et al. Perceived health and physical functioning in postpoliomyelitis syndrome: a 6-year prospective follow-up study. Arch Phys Med Rehabil 2003; 84: 1048–56.
86. Pentland B, Hellawell D, Benjamin J, et al. Survey of the late consequences of polio in Edinburgh and the Lothians. Health Bull (Edin) 2000; 58: 267–75.
87. Ahuja B, Gupta VK, Tyagi A. Paralytic poliomyelitis (1989–1994): report from a sentinel center. Indian Pediatr 1996; 33: 739–45.
88. Burger H, Marincek C. The influence of post-polio syndrome on independence and life satisfaction. Disabil Rehabil 2000; 22: 318–22.
89. Kumakura N, Takayanagi M, Hasegawa T, et al. Self-assessed secondary difficulties among paralytic poliomyelitis and spinal cord injury survivors in Japan. Arch Phys Med Rehabil 2002; 83: 1245–51.
90. Larsson Lund M, Lexell J. A positive turning point in life – how persons with late effects of polio experience the influence of an interdisciplinary rehabilitation programme. J Rehabil Med 2010; 42: 559–65.
91. Nollet F, Beelen A, Sargeant AJ, et al. Submaximal exercise capacity and maximal power output in polio subjects. Arch Phys Med Rehabil 2001; 82: 1678–85.
92. Chan KM, Amirjani N, Sumrain M, et al. Randomized controlled trial of strength training in post-polio patients. Muscle Nerve 2003; 27: 332–8.
93. Agre JC, Rodriquez AA, Franke TM. Strength, endurance, and work capacity after muscle strengthening exercise in postpolio subjects. Arch Phys Med Rehabil 1997; 78: 681–6.
94. Spector SA, Gordon PL, Feuerstein IM, et al. Strength gains without muscle injury after strength training in patients with postpolio muscular atrophy. Muscle Nerve 1996; 19: 1282–90.
95. Klein MG, Whyte J, Esquenazi A, et al. A comparison of the effects of exercise and lifestyle modification on the resolution of overuse symptoms of the shoulder in polio survivors: a preliminary study. Arch Phys Med Rehabil 2002; 83: 708–13.
96. Willen C, Sunnerhagen KS, Grimby G. Dynamic water exercise in individuals with late poliomyelitis. Arch Phys Med Rehabil 2001; 82: 66–72.
97. Strumse YA, Stanghelle JK, Utne L, et al. (2003). Treatment of patients with postpolio syndrome in a warm climate. Disabil Rehabil 2003; 25: 77–84.
98. Bertelsen M, Broberg S, Madsen E. Outcome of physiotherapy as part of a multidisciplinary rehabilitation in an unselected polio population with one-year follow-up: an uncontrolled study. J Rehabil Med 2009; 41: 85–7.
99. Brogårdh C, Flansbjer UB, Lexell J. No effects of whole-body vibration training on muscle strength and gait performance in persons with late effects of polio: a pilot study. Arch Phys Med Rehabil 2010; 91: 1474–7.
100. Skough K, Krossén C, Heiwe S, et al. Effects of resistance training in combination with coenzyme Q10 supplementation in patients with post-polio: a pilot study. J Rehabil Med 2008; 40: 773–5.
101. Widar M, Ahlstrom G. Pain in persons with post-polio. The Swedish version of the multidimensional pain inventory (MPI). Scand J Caring Sci 1999; 13: 33–40.
102. Willen C, Grimby G. Pain, physical activity, and disability in individuals with late effects of polio. Arch Phys Med Rehabil 1998; 79: 915–19.
103. Vasiliadis HM, Collet JP, Shapiro S, et al. Predictive factors and correlates for pain in postpoliomyelitis syndrome patients. Arch Phys Med Rehabil 2002; 83: 1109–15.
104. Zapp JJ. Post-poliomyelitis pain treated with gabapentin. Am Fam Physician 1996; 53: 2442–45.
105. Trojan DA, Cashman N. R. Fibromyalgia is common in a postpoliomyelitis clinic. Arch Neurol 1995; 52: 620–4.
106. Ahlstrom G, Karlsson U. Disability and quality of life in individuals with postpolio syndrome. Disabil Rehabil 2000; 22: 416–22.
107. Thoren-Jonsson AL, Grimby G. Ability and perceived difficulty in daily activities in people with poliomyelitis sequelae. J Rehabil Med 2001; 33: 4–11.
108. McNeal DR, Somerville NJ, Wilson DJ. Work problems and accommodations reported by persons who are postpolio or have a spinal cord injury. Assist Technol 1999; 11: 137–57.
109. Lin MC, Liaw MY, Chen WJ, et al. Pulmonary function and spinal characteristics: their relationships in persons with idiopathic and postpoliomyelitic scoliosis. Arch Phys Med Rehabil 2001; 82: 335–41.
110. Weinberg J, Borg J, Bevegard S, et al. Respiratory response to exercise in postpolio patients with severe inspiratory muscle dysfunction. Arch Phys Med Rehabil 1999; 80: 1095–100.
111. Klefbeck B, Lagerstrand L, Mattsson E. Inspiratory muscle training in patients with prior polio who use part-time assisted ventilation. Arch Phys Med Rehabil 2000; 81: 1065–71.
112. Craig A, Moses P, Tran Y, et al. The effectiveness of a hands-free environmental control system for the profoundly disabled. Arch Phys Med Rehabil 2002; 83: 1455–8.
113. Ho TW, McKhann GM, Griffin JW. Human autoimmune neuropathies. Annu Rev Neurosci 1988; 21: 187–226.
114. Sheikh KA, Zang G. An update on pathobiologic roles of anti-glycan antibodies in Guillain–Barré sydrome. F1000 Biol Rep 2010; 2(pii): 21.
115. Hughes RA, Cornblath DR. Guillain–Barré syndrome. Lancet 2005; 366: 1653–66.
116. Lehmann HC, Meyer Zu Hörste G, Kieseier BC, et al. Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2009; 2: 261–81.
117. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain–Barré syndrome. Lancet Neurol 2008; 7: 939–50.
118. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain–Barre syndrome. Arch Neurol 2001; 58: 913–17.
119. Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30: 131–56.
120. Hughes RA, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain 2007; 130: 2245–57.
121. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain–Barré syndrome. Cochrane Database Syst Rev 6: 2010a; CD002063.
122. Lehmann HC, Hartung HP, Hetzel GR, et al. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006; 63: 1066–71.
123. Raphael JC, Chevret S, Hughes RA, et al. Plasma exchange for Guillain–Barre syndrome. Cochrane Database Syst Rev 2: 2002; CD001798.
124. Hughes RA, Swan AV, van Doorn PA. Corticosteroids for Guillain–Barré syndrome. Cochrane Database Syst Rev 2: 2010; CD001446.
125. van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barre syndrome: randomised trial. Lancet 2004; 363: 192–6.
126. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain–Barré syndrome. Arch Neurol 2005; 62: 1194–8.
127. Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain–Barré syndrome. Neurology 2011; 76: 968–75.
128. Grand'Maison F, Feasby TE, Hahn AF, et al. Recurrent Guillain–Barre syndrome. Clinical and laboratory features. Brain 1992; 115: 1093–106.
129. Rees JH, Thompson RD, Smeeton NC, et al. Epidemiological study of Guillain–Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64: 74–7.
130. Melillo EM, Sethi JM, Mohsenin V. Guillain–Barre syndrome: rehabilitation outcome and recent developments. Yale J Biol Med 1998; 71: 383–9.
131. Sarada C, Tharakan JK, Nair M. Guillain–Barre syndrome: a prospective clinical study in 25 children and comparison with adults. Ann Trop Paediatr 1994; 14: 281–6.
132. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain–Barré syndrome. Ann Neurol 2010; 67: 781–7.
133. Govoni E, Granieri E. Epidemiology of the Guillain–Barré syndrome. Curr Opin Neurol 2001; 14: 605–13.
134. van Koningsveld R, van Doorn PA, Schmitz PI, et al. Mild forms of Guillain–Barre syndrome in an epidemiologic survey in the Netherlands. Neurology 2000; 54: 620–5.
135. Cheng Q, Jiang GX, Fredrikson S., et al. Epidemiological surveillance of Guillain–Barre syndrome in Sweden, 1996–1997. Acta Neurol Scand 2000; 101: 104–10.
136. Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome in patients with Guillain–Barre syndrome requiring mechanical ventilation. Neurology 2000; 54: 2311–15.
137. Ropper AH. Severe acute Guillain–Barre syndrome. Neurology 1986; 36: 429–32.
138. Bernsen RA, de Jager AE, Schmitz PI, et al. Long-term impact on work and private life after Guillain–Barre syndrome. J Neurol Sci 2002; 201: 13–17.
139. Bersano A, Carpo M, Allaria S, et al. Long term disability and social status change after Guillain–Barré syndrome. J Neurol 2006; 253: 214–18.
140. Bernsen RA, de Jager AE, Kuijer W, et al. Psychosocial dysfunction in the first year after Guillain–Barré syndrome. Muscle Nerve 2010; 41: 533–9.
141. Khan F, Pallant JF, Ng L, et al. Factors associated with long-term functional outcomes and psychological sequelae in Guillain–Barre syndrome. J Neurol 2010; 257: 2024–31.
142. De Vries JM, Hagemans ML, Bussmann JB, et al. Fatigue in neuro-muscular disorders: focus on Guillain–Barré syndrome and Pompe disease. Cell Mol Life Sci 2010; 67: 701–13.
143. Esperou H, Jars-Guincestre MC, Bolgert F, et al. Cost analysis of plasma-exchange therapy for the treatment of Guillain–Barre syndrome. Intens Care Med 2000; 26: 1094–100.
144. Meythaler JM, DeVivo MJ, Braswell WC. Rehabilitation outcomes of patients who have developed Guillain–Barre syndrome. Am J Phys Med Rehabil 1997; 76: 411–9.
145. El Mhandi L, Calmels P, Camdessanché JP, et al. Muscle strength recovery in treated Guillain–Barré syndrome: a prospective study for the first 18 months after onset. Am J Phys Med Rehabil 2007; 86: 716–24.
146. Köller H, Kieseier BC, Jander S, et al. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005; 352: 1343–56.
147. Lewis RA. Chronic inflammatory demyelinating polyneuropathy and other immune-mediated demyelinating neuropathies. Semin Neurol 2005; 25: 217–28.
148. Vallat JM, Sommer C, Magy L. Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 2010; 9: 402–12.
149. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24: 311–24.
150. Vlam L, van der Pol WL, Cats EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2011; 8: 48–58.
151. van Schaik IN, Winer JB, De Haan, R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; 2: CD001797.
152. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004; 3: CD003906.
153. Joint Task Force of the EFNS and the PNS. Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15: 1–9.
154. Mehndiratta MM, Hughes RA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; 1: CD002062.
155. Nobile-Orazio E, Gallia F, Tuccillo F, et al. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr Opin Neurol 2010; 23: 519–23.
156. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136–44.
157. Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 802–7.
158. Donofrio PD, Bril V, Dalakas MC, et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 1082–8.